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ABSTRACT
This thesis describes investigations conducted to study
factors influencing the outcome of antifungal treatment
of denture stomatitis. Clinical, mycologic, haematolog'ic
and prosthodontic factors were evaluated. The humoral and
cellular immune responses were also studied. Two
antifungal agents were compared: systemically
administered fluconazole and topically administered
amphotericin. A total of 29 patients were randomised to
receive fluconazole 50mg daily for 14 days; 30 were
randomised to receive amphotericin lozenges and cream for
28 days. Patients were assessed at the time of entry into
the study and at one, four and twelve weeks thereafter.
There were no significant differences in clinical
response between the groups at any follow-up visit. The
best clinical response was observed after four weeks
whereas the best mycologic response was noted after one
week. At the 12 week assessment clinical evidence of
relapse and recurrence was a common finding irrespective
of treatment. Overall the correlation between mycologic
and clinical events was poor. Correlation was better in
those patients who demonstrated very poor and very good
clinical responses. Fluconazole appeared to be largely
ineffective against Candida glabrata.
Haematologic deficiencies were infrequent and appeared
not to affect clinical outcome. Clinical response in
non-smokers was better than in smokers and this
difference was significant at the one week visit. Denture
quality although generally poor appeared to exert no
marked influence over clinical outcome. Adverse reactions
to treatment were uncommon in both groups. Little change
was observed in serum and salivary total and
anti-candidal antibodies throughout the study. However
the humoral immune response in smokers appeared to be
depressed in comparison with non-smokers. Candidal
infection appeared to cause depression of the ability of
the cellular immune response to respond to
Candida antigen. This response would appear to be
restored following antifungal therapy. The results of
these investigations suggest that factors influencing the
short and long term success of antifungal treatment of
denture stomatitis are, the necessity for elimination of
yeasts from the mouth by the therapeutic agent, effective
denture hygiene, and smoking. Prosthodontic factors would
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All who drink of this remedy recover in a short time,
except those whom it does not help, who all die.




A REVIEW OF THE LITERATURE
PERTAINING TO DENTURE STOMATITIS
- 1 -
1. Historical Aspects
The first accounts of denture stomatitis in the medical
and dental literature date from around the turn of the
present century. Prior to this the occurrence of the
condition is speculative. A pre-requisite for the
development of the disease is the presence in the mouth of
a denture and it is known that the Phoenicians and
Etruscans constructed partial dentures as early as the
third and fourth centuries BC.1 These usually consisted
of human teeth fastened into the mouth with gold bands or
ligatures. Candidal infections of the mouth were also
known in ancient times. Hippocrates was almost certainly
describing Thrush when referring to two cases of oral
aphthae in individuals with debilitating illness.2
Whether candidal infections occurred in association with
primitive prostheses is unknown but it seems unlikely
given that mucosa was not covered to any great extent.
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Pierre Fauchard in "Le Chirurgien Dentiste", published in
1728, was the first to write extensively about prosthetic
dentistry1. He described complete dentures carved from
bone and retained by means of springs connecting the upper
and lower denture. Carved bone and ivory were to remain
the principal denture base materials for well over a
century and, given the approximate nature of their fit and
the force exerted by the springs, they must have resulted
in trauma to the underlying mucosa. Porcelain and gold
were also used as denture base materials at about this
time but all artificial teeth remained a luxury only a few
could afford.
Of more significance would be the advent of a denture base
material which could be made to fit accurately and which
could be produced cheaply. This material was to be
vulcanised rubber, invented by Charles Goodyear in 1851.
Vulcanite became the most widely used denture base
material and with improvements in impression techniques
and means of production, well fitting dentures, which
could be retained without the aid of springs, became
available to the masses.1
Amongst the first descriptions of what is recognisably
denture stomatitis is that of McKenzie3 who writes;
"If the patient wears a plate on the roof of the mouth and
this be removed, the underlying mucous membrane will be
found swollen and red"
- 3 -
he also considers that this is;
"a form of infection very common amongst those who use
false teeth where the utmost cleanliness is not observed".
McKenzie was writing after the introduction of vulcanite
and given the increased availability of dentures the
condition must have been increasingly observed by dentists
and physicians. It is understandable that Lain in 1932
considered the constituents of the material an underlying
cause.4
Cahn5 was probably the first to consider that the
condition might be associated with yeast infection, a view
shared later by Bartels6 and Stones7. Lyon and
Chick8 demonstrated the efficacy of antifungal therapy,
thus implicating Candida infection in the aetiology. In
their experiment, cure and improvement were effected
despite the fact that patients continued to wear their
existing dentures and they concluded that neither the fit
nor the material of the denture were directly responsible
for the condition. They did however consider that denture
trauma might be a predisposing factor.
In these early papers the beginings of a multi-factorial
concept of the aetiology of denture stomatitis can be
seen. Early treatment regimens consisted of leaving
dentures out at night and soaking them in a mild
- 4 -
hypochlorite solution5 , in addition to the use of
therapeutic agents such as Gentian Violet5 and Sodium
Caprylate Jelly8.
2. Nomenclature
There are a number of terms which are synonymous with
"Denture Stomatitis" in that they have been used in the
dental literature as names for the same clinical entity.
These terms are listed in Table 1. "Denture Sore Mouth"
probably replaced "Rubber Sore Mouth" in general usage
when vulcanised rubber ceased to be used as a denture base
material. However Cawson15 found that soreness was not a
prominent feature of the disease and suggested that
"Denture Sore Mouth" was a misnomer. Both Neill16 and
Cawson17 proposed "Denture Stomatitis" as a more
suitable name.
Both "Denture Stomatitis" and "Denture Induced Stomatitis"
are satisfactory terms. "Denture Induced Stomatitis" is
probably preferred by those who feel that "Denture
Stomatitis" implies a condition of the denture rather than
of the patient, although this does seem somewhat pedantic.
Both terms lack precision in that they might be taken to
refer to any inflammatory condition of the mouth related















trauma from an over-extended denture flange could be
included under this heading. However few, if any, authors
on this subject have included such lesions in their
descriptions of the condition.
There is a significant body of evidence to support the
involvement of Candida organisms in the aetiology of
denture stomatitis (vide infra). This has lead to the
inclusion of terms such as "Candidosis" in names for the
condition. However the terms suggest a precise diagnosis
which cannot be made from clinical observation alone and
must be proven by other means. "Chronic Atrophic
Candidiasis" is not suitable since the mucosa is not
always atrophic18 and in any case a histological
examination would be required to demonstrate this.
"Chronic Erythematous Candidosis" is also problematic in
that chronic erythematous lesions have been shown to
affect non-denture bearing tissues.19 The pathogenesis
of such lesions is probably quite different to those of
denture stomatitis and the use of the same name for both
conditions may not be desirable.
There is further controversy over the use of "Candidiasis"
or "Candidosis". The present consensus would appear to
favour the suffix -osis which is consistent with the
ending used for almost all other fungal disease
names.20,21
- 7 -
To summarise, "Denture Stomatitis" is a simple, well
understood name. It refers to a distinct clinical
condition and is therefore as specific as it needs to be.
In the context of an individual or a group with this
clinical condition, in whom candidal infection is proven,
a more precise term may be used and "Candida-associated
Denture Stomatitis" seems to be as good as any.
3, Clinical Aspects
(a) Classification
Classifications of the condition have been based largely
on the clinically observable inflammatory changes of the
maxillary denture bearing mucosa. The clinical material of
Nyquist22 and Ostlund23 fell into three categories:
small localised areas of redness, more generalised redness
covering the whole of the denture bearing area, being
sharply demarcated from the surrounding, healthy,
non-denture bearing mucosa, and a third form in which the
mucosa had a granular appearance. Newton's24 description
is essentially similar and has given rise to Newton's
types 1, 2 and 3, as a popular classification. This is a
little surprising given that Newton's paper is aimed at
- 8 -
establishing a specific aetiology for denture stomatitis
based on rather weak theoretical similarities with the
histological and clinical characteristics of the Sweat
Retention Syndrome. With this in mind he describes the
localised form of inflammation as "pin-point hyperaemia"
which surrounds the orifices of the ducts of minor
salivary glands. Hence investigators may be guilty of
using "Newton type 1" rather loosely when they wish to
describe a patchy type of erythema. Budtz-Jorgensen and
Bertram25 chose the terms simple localised, simple
diffuse and granular to describe the same three variants.
Bergendal and Isaacson18 declined to include the
localised form of erythema in their classification since
they considered sufficient evidence exists to implicate
trauma alone as the cause of this condition. The diffuse
and granular type of inflammation they consider should be
referred to as atrophic and hyperplastic respectively.
This is despite the fact that in their investigations many
cases of so called atrophic denture stomatitis showed
normal epithelial thickness. They also admit that erythema
may be the result of increased vascularity rather than
mucosal atrophy. Such inconsistencies must lend support to
the observation of Holmstrup and Axell26 that





usually localised to tne inriamea area; also of dryness of
the mouth and bad tastes.15>18>22•25 • 27"3 1
Patients with denture stomatitis may complain
a burning sensation, itching or tingling, all
Nyquist22 found such symptoms to be uncommon and
Cawson15 found the degree of soreness to be variable and
unrelated to the severity of inflammation. However Ritchie
et al27 and Olsen2 9 found 45% and 44% of their
patients, respectively, had symptoms. Two studies have
reported symptoms according to inflammatory type and both
found soreness to be commonest in the diffuse type of
inflammation (59%25 and 36.8%18).
These results should be interpreted with caution as
symptoms such as burning, dryness etc., also occur in
individuals without denture stomatitis. Dorey et al31
reported that 28% of their patients with denture
stomatitis complained of subjective symptoms, as did 19.9%
of the controls. Of these latter it was estimated that
psychological factors were involved in about one third. On
a practical level denture stomatitis, when present, will
usually be considered as the most likely cause of such
symptoms. There is some justification for this since
studies have demonstrated that resolution of denture
- 10 -
stomatitis is often accompanied by resolution of
symptoms.15,29,32
(c) Associated oral conditions
A number of oral conditions have been described in
association with denture stomatitis, most commonly,
angular cheilitis. Angular cheilitis has been reported in
approximately one third to one half of patients with
denture stomatitis (see Table 2). This is commoner than in
individuals with healthy oral mucosa18'35 . The
relationship between these two conditions has lead some to
the view that they are part of the same clinical disease
entity11 especially since Candida species have been
shown to be involved in angular cheilitis.36'37 However
the infective aetiology of angular cheilitis is complex
and Staphylococcus aureus would appear to be even more
significant than Candida.38 • 39 Despite this, treatment
of denture stomatitis often leads to healing of the
angular lesions also.17'29'32
J
Other oral candidoses have been associated with the
presence of denture stomatitis, namely; thrush15,
glossitis15'18'25'40 and candidal leukoplakia.18'41
This does not seem surprising and may be a result of
increased candidal loading in the mouths of denture
- 11 -
TABLE 2
INCIDENCE OF ANGULAR CHEILITIS IN PATIENTS
WITH DENTURE STOMATITIS
Lyon and Chick 19578 33%
Cawson 196315 54%
Makila 196933 37%
Ritchie et al 196927 41%




Bergendal and Isaacson 198318
atrophic 31.6%
hyperplastic 34.5%
Wilkieson et al 199135 54%
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wearers, or of increased susceptibility to candidal
infections in these individuals, or both.
4■ Prevalence
Denture wearing, particularly complete denture wearing, is
commoner amongst older individuals than it is amongst
younger individuals. As a result almost all enquiries into
the prevalence of denture stomatitis have been surveys of
elderly populations. The population samples studied fall,
with one or two exceptions, into three groups:
1. Randomised samples, chosen to be representative of the
elderly population as a whole.42-47
2. Samples of those living in nursing homes, hospitals
etc.,(institutionalised elderly).35' 48-55
3. Samples of those attending dental hospitals.22'56
The studies in group 1 are more commonly representative of
the elderly living independently within the community
rather than of the entire elderly population.
It might be useful to make comparisons between the
results of studies in the different population groups
- 13 -
above. However even comparing studies within the same
group presents difficulties. Examination techniques and
diagnostic criteria have differed considerably, as have
the methods by which the samples are chosen and the way in
which the results are presented. The prevalence rates
quoted may refer to the entire population studied or only
the population at risk, i.e. denture wearers. These
features, together with varying socioeconomic and
demographic factors, may explain the considerable range of
reported prevalence.
Of the type of study in group 1 the lowest prevalence
reported was 16.3% in a rural community in the USA47,
whereas the highest was 65% in three Danish towns of
differing size and location.43 Hoad-Reddick, Grant and
Griffiths57 looked at a combination of institutionalised
elderly and those living in the community, in a United
Kingdom Health Authority area, where they found a
prevelance of 7.3%. Tobias58 surveyed residents in
sheltered accommodation in West Essex where the prevalence
was found to be 9%. In both of these UK studies the
prevalence appears to be very low. An earlier UK study44
found denture stomatitis in 20.5% of the elderly
population and, from the information given, in
approximately 29% of those wearing dentures. This figure
is nearer the average from other countries.
- 14 -
The reported prevalence in the institutionalised elderly
varies between 19%53(USA, Peru, Argentina and Israel)
and 54%54(Scotland). Nyquist22 found denture
stomatitis in 27% of a series of dental hospital patients
whilst Budtz-Jorgensen56 reported 75% of women and 55%
of men had denture stomatitis, also in a series of dental
hospital patients. Dental hospital patients tend to be
highly selected populations and differences can be
expected.
Denture stomatitis has been reported as commoner in
women22-45*55'56 whilst other studies have found no
difference in prevalence between males and
females.35•46>49•50 No studies have shown denture
stomatitis to be commoner in men. It has been found to be
increasingly common with age52, decreasingly common with
age42-45'49'50 and to have a prevalence unrelated to the
age of the individuals studied.46'54'55 One reason given
for the more often observed decreasing prevalence with
increasing age is that older individuals may be less
embarrassed about leaving their dentures out at night and
using soaking agents for cleaning them. The prevalence of
denture stomatitis has been shown to be higher in complete
denture wearers than in partial denture wearers.42'45'60
A number of surveys have reported the proportions with
- 15 -
TABLE 3
PROPORTION OF INFLAMMATORY TYPES - FROM SURVEYS
OF THE PREVALENCE OF DENTURE STOMATITIS (%)
Ref. No. Localised Dif fuse Granular
46 74 21 5
50 33 35 . 5 31 . 5
51 54 . 7 37 . 7 7.6
54 61 . 5 27 . 7 10.8
55 51 . 8 37 . 1 11.1
59 62 . 9 15 . 2 21.9
- 16 -
the localised, diffuse and granular forms of denture
stomatitis and these are given in Table 3. The figures in
each row total 100%, representing the total number of
individuals with denture stomatitis, not the total
population studied. The percentages were, in some cases,
extrapolated from the numbers given. The majority of
studies show the localised type to be the commonest
followed by the diffuse type and then the granular type.
5. Aetiology
The aetiology of denture stomatitis has been said to be
multifactorial61'62. The factors which are claimed to
contribute to the aetiology of denture stomatitis will be
reviewed under the following headings:
(a) Micro-organisms and denture plaque
(b) Trauma from dentures
(c) Allergy and primary irritant reactions.
(d) Host-related factors.
- 17 -
(a) Micro-organisms and denture plaque.
Writing in 1918 McKenzie3 seemed aware that denture
stomatitis was associated with poor denture hygiene.
Cahn5 was probably the first to consider the disease had
a specific infective aetiology. Both he and Bartels6
were able to consistently isolate Candida albicans from
the mouths and dentures of patients with denture
stomatitis. Later investigators were able to demonstrate
that yeasts could be cultured far more frequently from the
mouths of patients with denture stomatitis than from the
mouths of denture wearers with healthy
mucosa8'15'25'49'54-63'64 and also that yeasts could be
more often isolated from dentures than from mucosal
surfaces.35'49-64 However it is apparent from these
reports that yeasts were cultured from a variable number
of patients with healthy mucosa and there is a recognition
that Candida albicans and other yeast species may exist
in the mouth as harmless commensal organisms.
Budtz-Jorgensen, Stenderup and Grabowski43, in a random
sample of the elderly Danish population, showed that
yeasts could be isolated from the mouths of 93% of those
with denture stomatitis. However the yeast carriage rate
amongst denture wearers with healthy mouths was 86%. It is
clear that a causative role for yeasts cannot be
postulated simply on the basis of more frequent isolation
in individuals with the disease.
- 18 -
Cawson15 suggested that denture stomatitis was caused by
an increase in the numbers of yeast organisms in the
mouths of individuals with the disease. Davenport,34 by
direct microscopic examination of smears taken from the
fitting surface of dentures showed that Candida occurred
in significantly greater quantities in patients with
denture stomatitis than in denture wearers with healthy
mucosa. Further, very dense colonisation by Candida was
observed on the denture fitting surface far more often
than on the palatal mucosa, in both patients and controls.
It was concluded that denture stomatitis is associated
with proliferation of Candida primarily within plaque on
the fitting surface of the denture. A number of other
workers, using culture techniques and direct microscopy of
smears, have provided evidence to support this
view25 i 6 5 - 7 2 #
Arendorf and Walker66 compared different techniques for
detecting and quantitating yeasts in dentate individuals,
denture wearers with healthy mucosa and those with denture
stomatitis. A number of mucosal sites were sampled in
addition to the denture fitting surface where relevant.
The imprint culture technique gave the greatest yield of
Candida at the various sites. The fitting surface of
complete dentures, the tongue, palate and cheeks were the
most frequently and densely colonised sites. There was a
- 19 -
highly significant increase in density of candidal
colonisation of all mucosal sites in normal denture
wearers compared with dentate subjects. In denture
stomatitis highly significant increases in candidal
densities occurred in both upper and lower denture fitting
surfaces, anterior palate and posterior tongue. In the
dentate the mean candidal colony count did not exceed 30
colonies per square cm of mucosa and in denture wearers
the maximum was 49 colonies/cm2 . In denture stomatitis
colony growth was frequently confluent. They conclude that
a prosthesis encourages the presence and growth of
candidal species which are strongly implicated in the
pathogenesis of denture stomatitis. They suggest that the
imprint culture technique might be used to differentiate
between the carrier and disease states given the maximum
colony counts described above. However the usefulness of
this suggestion seems questionable and has been
challenged3 5 .
Denture plaque would appear to be a rapidly forming
microbial plaque consisting largely of bacteria69'72.
Significantly greater numbers of bacteria have been
demonstrated in the denture plaque of denture stomatitis
patients compared with that of healthy denture wearing
controls69. The plaque on the fitting surface has been
shown to harbour significantly more yeasts than that on
the buccal flange and it would appear therefore that
- 20 -
conditions beneath the denture favour yeast
colonisation68. Although yeasts have been shown to
constitute less than 1% of bacterial counts in denture
plaque their numbers are many times greater in the plaque
of denture stomatitis patients than in the plaque of
denture wearers with healthy mucosa69'72. In addition it
has been pointed out that yeast cells and hyphae in
particular are considerably larger in size than most
bacteria.
Using an impression culture technique a close
topographical relationship between the location of
candidal colonies and areas of palatal erythema has been
demonstrated25'66. Santarpia et al73 cast C.albicans
specific growth media into dentures and were able to show
this topographical relationship only in Newton type III
cases. However there was a general correlation between the
severity of inflammation and the number of C.albicans
colonies on the agar replica. The density of candidal
colonisation of the denture fitting surface has been shown
to be closely correlated with the degree of palatal
erythema70'71. The same studies showed a similar
relationship between erythema and Candida colony counts
in saliva. Tamamoto et al70 also showed a correlation
between denture plaque scores and the grade of denture
stomatitis, and between fungal concentration and plaque
accumulation. Tarbet67 also reported a correlation
- 21 -
between plaque levels and erythema, and between Candida
counts and erythema. However he was unable to show a
correlation between denture plaque levels and Candida
counts. He interprets this as indicating that plaque
levels and Candida exert independent effects. However in
this study the Candida were derived from the mucosa, not
the denture surface, and this might just as easily account
for the lack of correlation.
With regard to the various yeast species which have been
isolated, no difference has been found between the yeast
flora of patients with denture stomatitis and that of
controls43'64'69. Candida albicans has been by far the
most frequently isolated species in both health and
disease15 >25 • 34 • 43>5 1 >64 " 66 • 69 • 70 ■ 7 1 . In contrast one
study found Candida glabrata to be the commonest species
in the population sample studied54. Wilkieson et al35
found that Candida albicans was the most frequently
isolated organism in their study group as a whole but that
in patients with denture stomatitis Candida glabrata
predominated. The virulence of Candida species may vary
and is thought to be dependent upon a number of
factors74. Amongst the most important of these factors
is adherence and Candida albicans has been shown to
adhere more readily to both mucosal and acrylic surfaces
than other species75. This may explain its apparent
predominance in both carriers and diseased individuals.
- 22 -
Candida albicans would appear to be isolated in pure
culture more often than in combination with other
species25-35'65 although it may be difficult to identify
mixed growth unless specific culture media is used76.
It has been shown that a number of different strains of
C.albicans are involved in denture stomatitis.77'78
These studies failed to produce conclusive evidence that
a particular strain was involved in the aetiology.
However Martin and Lamb79 demonstrated that
C.albicans isolates from the denture fitting surface
and palate of patients with denture stomatitis were
almost exclusively serotype A compared with a mixture of
serotype A and serotype B isolates found on the buccal
mucosa of the same patients and at all sites in controls.
They concluded that infection is associated with the
proliferation of a single serotype to the exclusion of
the other and that this proliferation is localised to the
site covered by the denture. There is also experimental
evidence from animal and in vitro models that certain
strains of C.albicans are more virulent than
others.80'81 McCourtie and Douglas81 compared the
adherence to acrylic and buccal epithelial cells of
strains isolated from active infections and from
asymptomatic carriers. Growth in media containing high
concentrations of sucrose and galactose increased the
adherence of infective strains many times, whilst only
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small increases in carrier strain adherence were
observed. The same infective strains were also more
virulent in mice. It would appear that the infective
strains were able to modify their surface composition in
response to high concentrations of certain sugars in
growth media and that this enhanced their virulence.
A number of studies have indicated that the pathogenesis
of denture stomatitis is associated with the presence of
Candida albicans in its hyphal form.17'25'34 Evidence
from an experimental model in monkeys would appear to
support this view.82 Alison and Douglas83 examined
the fitting surface of temporary soft lining materials,
from patients with denture stomatitis, by light microscopy
and demonstrated micro-colonies of Candida with hyphae
projecting from the denture fitting surface.
On the other hand abundant hyphae have often been
demonstrated in denture wearers with healthy
mucosa43'66'84 and blastospores have occasionally been
found to be the only morphologic form present in patients
with denture stomatitis.66'84 By infecting mice with
morphologic mutants of Candida albicans, Shepherd85
has produced compelling evidence that either yeast or
mycelial forms are capable of producing disease.
Interestingly Holbrook et al80 showed, in experimental
oral infection of mice, that a virulent strain of
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C.albicans produced few, short pseudohyphae whilst an
attenuated strain produced abundant, long pseudohyphae.
Rebora et al86 found mycelial forms to be rare in
experimental infection of human skin. Clearly the
contention that hyphae are the sole pathogenic form of
C.albicans is difficult to sustain.
It has been suggested that the morphologic form of
C.albicans is merely a product of local environmental
conditions, in particular the pH.62>82 Denture plaque
in patients with denture stomatitis is more acidic than
that in healthy controls,84'87 particularly following
sucrose rinses.84-88 However no relationship could be
demonstrated between the pH of resting denture plaque and
the occurence of hyphae.8 4 - 8 8 The pH of denture plaque
may well be associated with the pathogenesis of denture
stomatitis but it does not seem to be responsible for the
conversion of C.albicans from the yeast to the mycelial
form in vivo.
Denture plaque has been studied by electron
microscopy83'89-93. The descriptions differ in detail
but essentially the plaque is largely bacterial and is
attached to the acrylic surface via a pellicle; yeast
organisms are rare. The pellicle has been further
characterised and would appear to differ from that formed
on enamel94 . In patients with denture stomatitis the
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pellicle was found to contain serum products, degradation
products and C.albicans cell components that were not
detected in the pellicle from healthy patients. Catalan
et al89 compared plaque from patients with denture
stomatitis and from those with healthy mucosa. Patients
with denture stomatitis had thicker plaque which
contained yeasts. Theilade and Budtz-Jorgensen90 found
no substantive difference between the denture plaque of
those with denture stomatitis and those with healthy
mucosa. In one sample the plaque contained only yeasts
whilst no yeasts were seen in any other. This was despite
demonstrating the presence of yeasts, by light
microscopic examination of smears, in the plaque of all
patients with denture stomatitis.
Frank and Steuer91 found that thick denture plaque
tended to consist largely of bacteria with only scattered
yeasts whilst in thin plaque yeasts predominated. In this
study only the plaque of patients with denture stomatitis
was observed. Cytological signs of degeneration have been
observed in plaque yeasts when in close association with
large numbers of bacteria, suggesting yeast-bacteria
antagonism91'92. It would appear that the intercellular
spaces of the palatal epithelium harbour bacteria and
yeasts92*93 and that renewal of denture plaque occurs
by proliferation of organisms from this site93. Frank
and Steuer91 often observed micro-organisms present
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It would appear from the findings of electron microscopy
studies that denture plaque is extremely heterogenous,
with bacteria predominating in some areas, yeasts in
others. Bacteria may be important in allowing the initial
attachment of yeasts to denture plaque but if local
conditions favour bacterial growth, yeasts may suffer as
a result, and vice versa.
Palatal candidosis has been induced by the inoculation
of Candida beneath acrylic plates in monkeys82'96-98
and rats99-101. In monkeys, an erythematous response was
produced with a similar histologic appearance to denture
stomatitis in man82. However this resolved
spontaneously after 2-3 weeks and could only be sustained
by repeated inoculation and use of topical tetracycline.
In one animal wearing a plate but with no Candida
inoculum beneath it, localised erythema occured around
the orifices of the palatal minor salivary glands. Two
studies using a rat model have divided the animals into
four experimental groups99'100; untreated animals,
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animals wearing a plate but with no Candida inoculum,
plate plus inoculum and inoculum only. Olsen and
Bondevik99 reported the most severe inflammation in the
plate plus inoculum group. Sporadic inflammation was
seen in other experimental animals but Candida was
isolated from many of the animals prior to the study
which complicates interpretation of these results. In the
study by Shakir et al100 no yeasts were isolated from
the rats prior to the start of the study. They found that
inflammation occurred only in the animals wearing a plate
with Candida inoculated beneath it. This began as
localised inflammation and spread to involve the whole of
the area covered by the plate. The inflammatory response
resolved when the plates were removed but Candida
persisted in the mouths of the rats100'101. When the
plates were subsequently re-inserted, without a further
inoculum, the inflammation returned101. This was
interpreted as indicating that the plate caused
conversion of the Candida to its more pathogenic
form (hyphae). However no attempt was made to quantify
the number of yeasts present at any stage and an increase
in the number of yeasts, held in close approximation to
the mucosa, seems just as likely an explanation for the
sequence of events observed. Some studies demonstrated
hyphal invasion of the mucosa100*101 whilst others did
not8 2'9 9 .
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Relatively few studies have been unable to show a
relationship between candidal growth and denture
stomatitis9 >18 - 5i . Nater et al9 used an unusual
method of isolating Candida, in that culture media were
cast in the form of the upper denture and then applied to
the palatal mucosa. Bergendal and Isaacson18 also used
a somewhat indirect method. In the epidemiological study
by Schou et al5 1 the overall recovery of Candida was
low at 38.6% of the population, which must cast doubt on
the methods used. Monaco and Pickett102 denied the
involvment of Candida in the hyperplastic form of the
disease, although this conclusion was based on the
absence of hyphal invasion alone.
The role of bacteria has received scant attention despite
the fact that bacteria are generally far more numerous in
denture plaque than yeasts69»72>90. The bacterial flora
would appear to consist of Gram-positive cocci and short
rods both in patients with denture stomatitis and in
controls69'72. However Koopmans et al103 did find
differences between the bacterial flora of patients and
controls. In individuals with denture stomatitis the
percentage of the bacterial flora which consisted of
cocci was lower than in healthy, denture wearing
controls. The denture stomatitis group had higher
percentages of obligate anaerobic bacteria in both
denture and palatal plaque. Invasion of the epithelium
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and sub-epithelial tissues by bacteria has been
demonstrated104. On the other hand, when smears from
the palate and dentures of denture stomatitis patients
were examined, leucocytes were seen more frequently in
association with yeasts than in association with
bacteria43. This suggests that yeasts rather than
bacteria are responsible for eliciting the inflammatory
response. Nonetheless bacteria are important in the
formation of denture plaque91-95. The possibility that
bacteria themselves may have a direct pathogenic effect
in denture stomatitis cannot be ruled out and requires
further study.
Whatever the specific nature of denture plaque,
clinical25 and epidemiological49~51 - 55 studies have
shown that plaque occurs in significantly greater
quantities on the dentures of patients with denture
stomatitis than on the dentures of individuals with
healthy mucosa. Studies have also shown a significant
positive correlation between plaque accumulation and
palatal erythema scores67-70. Ambjornsen46 showed an
increased prevelance of denture stomatitis in those with
poor denture hygiene but this was not statistically
significant. However Mikkonen et al105 and
Nyquist106 found that the frequency of denture brushing
did not significantly effect the prevalence of denture
stomatitis. It has been suggested that the poor denture
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cleanliness seen in denture stomatitis patients may be
due to leucocyte emigration and the continuous shedding
of epithelial cells from inflamed mucosa rather than to
neglected hygiene25. Schou et al51 were able to find
no relation between denture plaque and brushing habits,
whereas they were able to demonstrate a significant
relation between denture plaque, soaking habits and the
presence of denture stomatitis. This seems to indicate
that brushing is not the most efficient means of removing
denture plaque, at least when frequency of brushing is
used as a measure.
(b) Trauma from dentures.
The first serious investigation of the role of trauma
from dentures in the aetiology of denture stomatitis was
that of Nyquist22. He examined over one thousand
patients and assessed the marginal fit, surface fit,
centric occlusion, articulation and vertical dimension of
their complete dentures. Fit was recorded as stable or
unstable and the occlusion was either correct or
traumatising. This demonstrates one of the difficulties
of investigating the effect of denture trauma, namely the
rather crude and subjective means of assessment. Nyquist
seems to have gone to some trouble to calibrate his
observations against those of other clinicians and
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claimed a remarkably small degree of discrepancy. He
demonstrated that as the number of traumatic denture
factors increased, so did the incidence of denture
stomatitis. However there was no correlation between the
extent of the area of erythema and the degree of trauma.
Neither was any attempt made to measure denture hygiene
or candidal infection.
Bastiaan107 carried out a very similar study to Nyquist
and their results with respect to trauma were in
agreement. However he also assessed denture hygiene and
the presence of Candida. He found patients with denture
stomatitis to have poorer hygiene and a higher incidence
of Candida colonisation compared with controls. Both
Bastiaan107 and Budtz-Jorgensen and Bertram25, in
addition to assessing the dentures, also assessed the
alveolar ridges with respect to their ability to offer
good retention and stability for dentures.
Budtz-Jorgensen and Bertram25 showed that poor ridge
morphology predisposed to denture stomatitis. The
localised form of inflammation was apparently associated
with unbalanced occlusion and low Candida colony
counts. On the other hand colonies grown using an
impression technique correlated closely with the
localised areas of inflammation. This could indicate that
trauma predisposes to yeast infection. Trauma may be due
to micro-roughness rather than macroscopic defects.108
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Newton24 suggested that a closely fitting denture would
restrict the flow of saliva from the ducts of the palatal
minor salivary glands and this would give rise to the
appearance of pin-point hyperaemia around the duct
orifices. This does not appear to be the same clinical
entity as the localised, patchy form of erythema
described by others22'25. Newton goes on to suggest
that the generalised form of inflammation is caused by
lateral spread of the saliva into the tissues, which is
less plausible. Ritchie et al27 have disputed this
theory claiming that denture stomatitis begins in the
anterior palate where there are no salivary glands.
Newton's paper was entirely theoretical and contained no
original data. It serves to illustrate that differences
can arise in the definition of "trauma". It would seem
that a traumatic denture can be either closely or loosely
fitting. If trauma is related to instability as has been
suggested22'107, the incidence of denture stomatitis
ought to be much higher in the mandible where the
residual ridge is frequently extensively resorbed.
Nyquist22, in his large series, found no cases of
denture stomatitis in the mandibular mucosa. This would
accord with clinical observation and the fact that very
few investigators even mention the lower denture bearing
area. Despite these contradictions a number of studies
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have indicated a relationship between traumatic denture
factors, such as poor fit and occlusion, and the
incidence of denture stomatitis22■25>42>46>63•107>109 .
There is an alternative interpretation of these studies,
which is that inflammation induced by factors other than
trauma causes changes in tissue shape which itself leads
to poor fit and occlusion of the dentures.
Not surprisingly the incidence of denture related lesions
is increased in patients who visit their dentist
infrequently47'105. This may be related to the age of
the dentures46'105 which become progressively more
traumatic as the ridges resorb and occlusal surfaces
wear, or it may be due to a lapse in denture hygiene in
the absence of professional encouragement105. Of course
both factors could be involved. Unfortunately patient
satisfaction with dentures seems to increase the longer
they are worn110 and the need for regular denture
servicing is not perceived by denture wearers44'58.
Pin-point hyperaemia of the ducts of the palatal salivary
glands was produced in one monkey by covering the palate
with a closely fitting acrylic plate82 . However the
animal was not gnotobiotic and therefore the role of of
infection in this case remains uncertain. In rats,
inflammation could only be induced beneath acrylic
palatal appliances when Candida was inoculated on the
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fitting surface100'101. The inflammation was initially
patchy and later became diffuse100.
The prevalence of denture stomatitis has been shown to
decrease with increasing age4 2 , 4 5 , 4 9 , 5 o # Nyquist22
made the same observation and suggested that this might
be due to decreasing muscle power in elderly
individuals, who were thus less likely to traumatise the
denture bearing mucosa as a result of occlusal
overloading. It has certainly been shown that subjective
soreness beneath dentures may be the result of
stress-induced muscle activity111 and psychological
factors may also be involved9. The role of occlusal
loading in the aetiology of denture stomatitis remains
speculative but would appear to be worthy of further
investigation.
Samaranayake et al112 showed that the adhesion of
Candida to acrylic strips was enhanced by coating the
strips with serum and reduced by coating with mixed
saliva. They suggested that denture trauma may result in
the production of an inflammatory exudate which would
enhance adhesion to, and therefore colonisation of, the
denture fitting surface by Candida. Saliva would appear
to have a protective effect, and this would help to
explain the very low incidence of denture stomatitis
beneath lower dentures22 where, due to the inevitable
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poor denture retention, ingress of saliva is possible.
The barrier properties of oral mucosa are affected by
denture wearing113 and indeed permeability is
considerably increased when the mucosa becomes
inflamed113-114. This is another possible means of
interaction between trauma and infection; traumatised
mucosa being more permeable to soluble microbial toxins
and antigenic components.
The appearance of the granular or "papillary" form of
denture stomatitis has lead some to the view that
negative pressure (suction) is involved in its
aetiology63'115. Nyquist22 found papillary
hyperplasia to be associated with the presence of a
palatal vacuum chamber and Sheppard et al110 found
the incidence of papillomatous lesions to be increased in
subjects with maximal denture retention. Also the role of
yeasts in this condition has been refuted102, although
only on the grounds of absent hyphal invasion.
A number of investigators have been unable to demonstrate
any significant correlation between trauma from dentures
and denture stomatitis9'50'55, although the study by
Nater et al9 related more to symptoms of soreness than
to denture stomatitis as such.
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(c) Allergy and primary irritant reactions.
Lain4 reported cases of oral mucosal lesions which were
presumed to be due to overcoloured or undercured
vulcanite dentures. Such appliances were often provided
by "cut rate dentists". Galvanic reactions between
dissimilar metals present in the mouth were also said to
be responsible for such lesions.
Allergic reaction to an acrylic denture base has
occasionally been cited as the cause of denture
stomatitis116'117. Acrylic resin contains a number of
constituents which are potential haptens in the
initiation of an allergic contact stomatitis118'119.
Turrell119 considered that Bradford's report120 of an
adverse reaction to newly fitted dentures was a case of
allergy to dibutyl phthalate, an acrylic plasticiser.
There are also reports of allergic reactions to
autopolymerising acrylic resin121'122'123 in which the
high level of residual methylmethacrylate monomer is said
to be the responsible agent. Such reactions should be
distinguished from primary chemical irritation. Giunta
and Zablotsky121 considered their case one of true
allergy since the response developed 24 hours after
exposure to the material. They consider that a primary
irritant reaction would have occurred much sooner.
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Nyquist22 showed that it was possible to produce an
allergic reaction in the oral mucosa. However he
investigated 248 cases of denture stomatitis and was
unable to find a single case of allergy. Turrell119
pointed out that methods of testing for acrylic allergy,
such as strapping the patient's denture to the forearm,
were quite unreliable as any positive response would
likely be due to trauma. He tested 50 patients with
denture stomatitis using filings from the patient's own
dentures. He found eight cases of supposed allergy and
these were all patients who had worn their dentures for
many years. He considered the allergenic properties of
these dentures to be due to contaminants absorbed during
years of use. Subsequent dentures constructed from
acrylic were well tolerated. It seems possible that the
contaminant was microbial plaque. Danilewicz-Stysiak116
reported four cases of acrylic allergy from 40 cases of
"denture sore mouth". However the descriptions of the
clinical status, history and patch testing technique are
far from clear.
Fernstrom and Oquist117 reported a case of denture
stomatitis apparently due to acrylic allergy. Filings
from the fitting surface of the patient's denture and an
unpolished acrylic blank both produced a severe reaction
on patch testing, whereas polished acrylic did not. They
- 38 -
postulated that the responsible allergen in the acrylic
occupied the surface layer and that this was removed
during polishing. This explained why the inflammatory
reaction was confined to the palatal mucosa, since the
fitting surface of a denture is not polished. In a
subsequent investigation124 the allergen was shown to
be acrylic monomer and a satisfactory denture was made
for the patient using the same acrylic but an altered
curing technique. Further studies of the same
patient125 involved the use of filings from an
unpolished denture which had never been used. Filings
from the fitting surface produced a positive response to
patch testing whereas filings from the vestibular surface
produced a negative response. This indicated that the
curing process was responsible for the location of excess
monomer in the fitting surface acrylic and that polishing
was irrelevant. It must be considered possible that the
reactions seen in this patient were of a primary chemical
irritant nature. Other such cases have been
described126-127, the patients usually complaining of
an intense burning sensation within a few hours of the
dentures being inserted. It would appear that, if a
denture has been incorrectly processed , high levels of
residual monomer may remain within it for a considerable
period of time afterwards126.
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Allergy to a cobalt-chromium denture base has been
reported128 and was apparently due to the nickel
content. Given that nickel allergy is quite common,
reports of contact sensitivity to cobalt-chromium denture
base alloys, which may contain varying amounts of nickel,
are extremely rare. It would appear that patients who are
sensitive to nickel may also be sensitive to cobalt129.
There are also reports of allergy to dental gold
alloys130,131t
High levels of acrylic monomer are capable of producing
an adverse response in the oral mucosa. Whether this is a
chemical irritation or true delayed-type hypersensitivity
may be difficult to determine. However the clincal
picture is clearly different to the more usual chronic
denture stomatitis. Allergy to metallic denture bases
would appear to be very rare but may be suspected as a
cause of inflammation beneath cobalt-chromium dentures in
patients who are sensitive to nickel.
(d) Host related factors.
A variety of host related factors can predispose to
denture stomatitis and may exert their effects either












The importance of these factors in the aetiology of
denture stomatitis relates mainly to the role of
Candida. A considerable number of factors have been
identified which may predispose to oral candidal carriage
and infection20-132"135. Only those relevant to denture
stomatitis will be considered here.
Denture wearing habits.
A number of studies have indicated that denture
stomatitis is a more frequent finding amongst those who
wear their dentures during both day and night, compared
to those who leave their dentures out at
night22*27'34'42'55. Love et al42 found this
difference to be particularly significant when patients
with severe inflammation were compared. Cases of more
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moderate inflammation occurred in equal numbers in those
who wore their dentures at night and in those who did
not.
The relationship between denture stomatitis and the
wearing of dentures both day and night may be due to the
constant effects of either denture trauma or microbial
plaque. Williamson136 demonstrated that patients who
wore their dentures at night had much higher early
morning Candida counts in saliva compared with patients
who left their dentures out at night.
Some studies have failed to show any relationship between
denture stomatitis and denture wearing habits25'35'137,
including what is probably the only prospective study of
this problem137 . In this investigation patients were
provided with new complete dentures and divided into two
groups. One group was instructed to wear the dentures
constantly whilst the other group were told to leave
their dentures out at night. When the patients were
re-examined one year later the incidence of denture
stomatitis was the same in both groups. Goss and
Chau138 showed that even wiring in dentures for
prolonged periods did not necessarily have a deleterious
effect on the oral mucosa.
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Dietary sugar.
There is evidence to suggest that a high intake of sugars
in the diet is associated with oral candidosis139»140.
Olsen and Birkeland140 found that sucrose rinses could
aggravate existing denture stomatitis and initiate
denture stomatitis in denture wearers with previously
healthy mucosa. This change in mucosal health was
accompanied by an increase in the density of Candida.
In vitro studies have suggested that glucose promotes
the growth of Candida in saliva141'142 and that this
growth is associated with a rapid decline in pH, which
may be associated with the pathogenesis of oral
candidosis142 . Sugar substrate would also appear to
enhance the ability of Candida to adhere to both
acrylic and buccal epithelial cells81'112.
Xerostomia.
The protective role of saliva against candidal
infection, both through its mechanical washing effect and
antifungal properties, is widely recognised135. However
there is no direct evidence that xerostomia leads to
denture stomatitis. Candida albicans may be found in
significantly greater numbers in the mouths of patients
with Sjogren's syndrome compared to healthy
individuals143. Suppressed salivary flow in monkeys
caused aggravation of inflammation produced by
inoculating Candida albicans beneath acrylic palatal
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plates98. Unsterilised human saliva inhibited the
growth of Candida141 and pre-coating strips of
acrylic with mixed human saliva reduced the adhesion of
Candida1 12 . All of these studies support the concept
that saliva has a protective role.
Smoking.
Two epidemiological studies have indicated that tobacco
smoking is associated with a significantly increased
prevalence of denture stomatitis47'54. Arendorf et
al41 found that tobacco smoking and denture wearing
were important contributory factors in the aetiology of
candidal leukoplakia. Approximately one third of patients
with this condition also had denture stomatitis. Smoking
has been claimed on one hand to increase144, and on the
other, to have no effect on145, the rate of oral
candidal carriage.
Nutritional deficiency states.
Cawson146 was the first to suggest an association
between anaemia and oral candidosis. Jennings and
MacDonald147 found that patients with haematological
abnormalities developed denture stomatitis in association
with less dense candidal colonisation than patients with
normal haematology values. Saliva from patients with
iron-deficient anaemia supported the growth of Candida
better than did saliva from controls148. Iron
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deficiency would appear to exert its effects through
defects in lymphocyte function148*149 although
Fletcher et al148 found impaired lymphocyte function in
iron-deficient patients both with and without mouth
lesions. This would seem to indicate the involvement of
some other factor in the production of clinical disease.
Jenkins et al150 were able to find no significant
differences in iron, folic acid and vitamin B12
deficiency between patients with denture stomatitis and
healthy controls. In a retrospective study151 cases of
iron and folate deficiency were found in association with
denture stomatitis. However correction of these
deficiencies had little or no effect on the long term
recurrence of the denture stomatitis.
Diabetes.
Candidal carriage has been shown to be more prevelant
amongst diabetic than amongst non-diabetic
individuals152*153. Whilst Tapper-Jones et al153 were
able to show that candidal density was also increased in
diabetic patients, Lamey et al152 could find no such
increase in candidal density but did demonstrate an
increased incidence of candidal infection amongst
diabetic patients. Peters et al154 could find no
increase in the prevalence of candidal carriage or in the
density of growth of Candida in diabetic patients, when
compared with controls.
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Saliva from diabetics has been shown to support the
growth of Candida and this was correlated with the
salivary glucose level141. Whilst investigators have
claimed that candidal carriage rate amongst diabetic
patients is dependent upon glycaemic control155, others
have denied such a relationship152,153,156,157 t
should be borne in mind when interpreting these studies
that methods of isolating Candida and of estimating
glycaemic control have varied considerably. Of more
direct significance, Phelan and Levin158 were able to
demonstrate no significant increase in the prevalence of
denture stomatitis in those individuals with either
diabetes mellitus or elevated plasma glucose levels
compared with individuals with normal glucose metabolism.
Antibiotics and corticosteroids.
There seems to be general agreement that the use of
broad-spectrum antibiotics in particular and
corticosteroids, to a lesser extent, may predispose to
the development of oral candidosis20■135. Knight and
Fletcher141 produced convincing evidence that
antibiotics promoted the growth of Candida by
inhibiting bacteria and thus removing the competition
for salivary glucose. The hyperglycaemic effect of
corticosteroids was considered responsible for promoting
candidal growth.
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McKendrick et al159 investigated patients with chronic
bronchitis who were receiving either continuous
tetracycline, intermittent tetracycline or a placebo.
They could find no relationship between the
administration of tetracycline and the prevalence or
relative numbers of oral Candida. Furthermore
McKendrick160 could find no significant relationship
between tetracycline administration and the occurrence
of denture stomatitis in what appears to be the same
group of patients.
There is experimental evidence from an animal model to
suggest that corticosteroids may exacerbate denture
stomatitis, possibly by suppressing cellular
immunity97 . Other than this there would appear to be no
direct evidence linking the use of corticosteroids to
denture stomatitis.
6. Histopathology.
A number of investigators have examined biopsy specimens
from the palatal mucosa of patients with denture
stomatitis and reported their findings18>23>161~163 .
Their observations have been quite consistent and the
main features seen are as follows:
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1. Complete absence of the keratin layer or
parakeratosis.
2. Epithelial hyperplasia with deeply penetrating rete
pegs, alternating with areas of epithelial atrophy.
3. Intracellular and intercellular oedema within the
epithelium.
4. Infilatration of the epithelium by leucocytes.
5. Chronic inflammation of the lamina propria usually
extending into the basal epithelial layers.
6. No evidence of hyphae or blastospores invading the
epithelium.
The granular form of denture stomatitis displayed much
the same histological appearance as the generalised
simple type except for the occurrence of papillary
projections in the former18'161'162. The papillary
projections consisted of either markedly hyperplastic
epithelium with a narrow core of connective tissue or
hyperplastic connective tissue with a covering epithelium
of almost normal thickness18. The crypts between the
papillae harboured microbial plaque and debris.
Budtz-Jorgensen161 divided his material into lesions
caused by trauma and those associated with Candida,
based on the presence of hyphal structures in smears
and the clinical response to antifungal and prosthetic
treatment. He could find no qualitative differences in
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the histopathologic appearances of the two types of
lesion. However, pronounced intraepithelial leucocyte
infiltration and the occurrence of leucocytes in smears
were seen more frequently in Candida induced lesions.
This investigation also showed that it was possible to
reverse the histologic changes by appropriate treatment.
However, in the granular form, subepithelial inflammation
persisted and this could be explained by the difficulty
of removing the contents of the deep epithelial crypts
described above. Another noteworthy feature of this study
was the significant correlation between intraepthelial
leucocyte infiltration and the quantity of yeast colonies
isolated.
Schiodt164 described an unusual clinical and
histological variant of denture stomatitis in which there
were intramucosal fistulae. These fistulae formed a
network running horizontally beneath the mucosal surface.
The inflammatory cell infiltrate in denture stomatitis
has been shown to consist mainly of T lymhpocytes, plasma
cells and macrophages165. This cellular infiltrate is
very similar to that found in chronic marginal
periodontitis and chronic apical periodontitis.
Ostlund23 found that in epithelium affected by denture
stomatitis there was a moderate increase in the number of
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cell mitoses compared with normal mucosa. In contrast Van
Mens et al166 found that denture stomatitis patients
had a significantly lower mitotic index in their palatal
epithelium compared with the epithelium of healthy
denture wearers. In experimentally induced palatal
candidosis in rats167, palatal epithelial thickness and
the number of mitotic figures were initially reduced but,
subsequently, both epithelial thickness and mitotic
activity showed a sharp increase. It may be that the
increase in cell mitoses, the consequent increase in
epithelial thickness and the shedding of the superficial
layers of the epithelium are a protective mechanism. The
same increase in epithelial thickness has not been
uniformly observed in humans, indeed it alternates with
areas of extreme atrophy18'23'161-163. The results of
experimentally induced palatal candidosis in rats
require careful interpretation. In this experimental
model hyphal invasion of the epithelium seems to be not
uncommon100'101, whereas in man it is remarkable by its
absence.161
7. Immunology
The inflammatory cell infiltrate in denture stomatitis
suggests that both cell mediated and humoral immune
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responses are involved in the disease process165. In
addition IgG, IgA, IgM and complement factor C3 have been
demonstrated in palatal mucosa in the granular form of
denture stomatitis168. Antigen-antibody complexes may
form which then activate complement and this process may
be responsible for the inflammation seen.
A number of studies have demonstrated, using various
techniques, that levels of serum antibodies to Candida
are increased in patients with denture stomatits compared
with controls11'56'169'170. According to Lehner17 0 ,
whilst most patients with oral candidosis demonstrated a
raised IgG level in particular, patients with chronic
atrophic candidosis also showed a marked increase in IgA
and IgM levels. Fouche et al171 investigated the serum
antibody response in eight patients undergoing treatment
with nystatin for denture stomatitis. In three patients,
serum antibodies to Candida fell following clinical
cure, then rose again gradually, but did not reach
pre-treatment levels. This was interpreted as indicating
that denture stomatitis in these three patients had been
caused by Candida. In other patients the serum antibody
response was more equivocal and this was taken to
indicate that the disease in these patients had a
different aetiology. However other studies have been
unable to demonstrate any clear relationship between
anti-Candida antibody titres in serum and either the
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degree of palatal erythema or the density of candidal
colonisation56-169. Bergendal and Holmberg169 found
that there was no change in serum antibody titres related
to the effect of antifungal treatment of oral lesions. It
is possible to detect levels of antibodies to Candida
in many individuals without oral infection56'169 and
this may indicate past infection, infection elsewhere in
the body, or simply carrier status. Furthermore zero or
low titres may occur in infected persons56. The role
of serum antibodies in denture stomatitis remains far
from clear but they would appear to have a limited role
in the diagnosis of this condition.
Titres of anti-Candida antibodies in saliva appear to
be significantly higher in patients with oral candidosis,
including denture stomatitis, than in non-infected
controls11'172'173. Oral carriers of Candida seem to
have intermediate levels of salivary antibody172. A
significant relationship has been shown between titres of
antibody to Candida in saliva and the number of colony
forming units of C.albicans in saliva173. Also the
level of anti-Candida antibody in saliva has been shown
to fall in response to antifungal treatment173 . The
most important antibody class in the mucosal immune
system is IgA. IgA has two subclasses, IgAl and IgA2.
Jeganathan et al173 demonstrated that in controls the
predominant subclass was IgA2 whereas in patients with
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clinical infection IgAl became the predominant subclass.
In a number of patients antifungal therapy reversed this
subclass alteration. Since IgAl is the predominant
circulating IgA subclass the possibility must exist that
the increased levels of IgAl in the saliva of the
patients was derived from serum, via the lesions, rather
than being a true change in the composition of the
secreted IgA in saliva. In any case the significance of
the findings is unknown. At least some of the secreted
IgA would appear to be able to inhibit the adherence of
Candida to epithelial cells172 and it has been
suggested that, although salivary antibodies are unable
to eliminate Candida, they may contribute to its
confinement to the mucosa174.
In contrast to some of the above studies Wray et al175
found that whilst levels of serum and salivary
anti-Candida IgG rose in infected patients, levels of
IgA tended to fall when compared with carriers and
non-carriers. This effect was more pronounced in HIV
positive individuals. The infected patients included some
with denture stomatitis. These observations are difficult
to explain. IgA synthesis in mice appears to be dependent
upon a seperate subset of regulatory T-cells in Peyer's
patches176. These T-cells predominantly help IgA
synthesis but T-cells may also exist which suppress IgG
synthesis. Consequently an antigen could induce a brisk
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IgA response at the same time as it supresses IgG or IgM.
This would seem to be beneficial as far as mucosal
immunity is concerned but quite why or how the reverse of
this could take place is not clear.
It is known that cellular immunity is important in
combating systemic fungal infections whereas humoral
immunity may be less important177 . In an experimental
monkey model, palatal candidosis tended to resolve
spontaneously after two to three weeks82. On
re-inoculation with Candida beneath the acrylic plate,
the inflammation recurred but was more pronounced and
this was assumed to be a delayed-type hypersensitivity
response. In the same experimental model the cellular
immune response was studied directly by observing in
vitro leucocyte migration96'97. The cellular immune
response was seen to reach its peak concomitantly with
the resolution of inflammation. However the agglutinating
serum antibody response occurred only after this
resolution had taken place. In monkeys treated with
azathioprine the clinical appearance of the lesion was
changed from one of atrophic candidosis to one of thrush
like lesions. Histologically there was hyphal invasion of
the superficial epithelial layers. This inflammation
persisted until after the azathioprine had been
discontinued. The cellular immune response was suppressed
by the azathioprine and did not occur until the drug was
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stopped. The humoral immune response in these animals was
early and strong but failed to clear the infection96. A
similar picture was observed in monkeys treated with
corticosteroids, which also suppressed the cell mediated
immune response97 . Both studies were taken to indicate
that cellular rather than systemic humoral immunity is of
primary importance in denture stomatitis. The cellular
immune response itself may be responsible for the typical
erythematous appearance of denture stomatitis. The role
of secretory antibodies was not studied in these
experiments and it seems likely that they were completely
excluded from the area of the lesion by the fastened in
plates.
It has been suggested that, in some patients, chronic
Candida infection may lead to suppression of the
cellular immune response178'179. Only 28% of patients
with granular denture stomatitis showed inhibition of
leucocyte migration compared with 94% of those with
localised inflammation178. In some patients, inhibition
of migration appeared to be restored by antifungal
therapy. There was an inverse relationship between
cellular immune response and serum agglutinins in
patients with superficial candidosis. However the
restoration of cellular immunity was unlikey to be
antibody mediated since the levels of serum antibody
remained unchanged in response to treatment. Davenport
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and Wilton179 found that the incidence of delayed
hypersensitivity to C.albicans was lower in patients
with denture stomatitis (12.5%), than in controls (26%).
They therefore denied that a cell mediated immune
reaction was responsible for the clinical appearance in
denture stomatitis but suggested that immune suppression
could be involved. In contrast, the function of
leucocytes taken from patients with denture stomatitis
was shown to be quite normal180'181. Also when
cellular immunity was deliberately depressed in monkeys,
the clinical and histologic nature of the lesions changed
completely.
The immunology of oral candidal infections is obviously
multi-faceted and therfore complex. Denture stomatits is
no exception and much of the evidence is conflicting.
There would appear to be a need for further studies of
all aspects of the immune response and their interaction
in the pathogenesis of this condition.
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8. Treatment
Given that many of the issues concerning the aetiology of
denture stomatitis remain unresolved it is not surprising
that the treatment regimens which have been advocated and
tested are many and varied. They fall into the following
categories:
(a) Antifungals.






A number of studies have investigated the efficacy of
the topically applied polyenes
nystatin1 2 • i 5 , 1 7 , 3 2 , 1 0 4 , 182-186 f ancj
amphotericin12•27•29>69•173>187 in the treatment of
denture stomatitis. Some of these studies demonstrated
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that patients could be completely cured12'17,27'32,
whilst others showed that although the majority of
patients were improved, only a small number were cured
completely from a clinical viewpoint15'69'182'185'186.
Nairn12 compared nystatin and amphotericin directly and
they appeared to be equally efficacious. It should be
remembered that the means of delivery of the drug has
varied considerably between studies and this would seem
to be an obvious explanation for the differences in
outcome. A common finding, however, was high rates of
relapse and recurrence following cessation of
treatment12'29'32'69'183. The reasons for this tendency
to relapse have been discussed by several authors and
include re-infection from exogenous sources as well as
from endogenous sites15'17'182. It would appear to be
difficult to eradicate yeasts completely, even from the
mouth1 2,187 t
Clinical improvement has usually been accompanied by
mycologic improvement, although following withdrawal of
the drug the density of candidal colonisation quickly
returns to pre-treatment levels2 7,3 2 ,l82 , l 85 , l 87 ,
Interestingly, one study found the clinical signs to lag
behind mycologic improvement by at least one week185.
Both nystatin and amphotericin would appear to produce
the greatest improvement in the clinical condition in
those patients with initially high yeast counts32'69.
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Indeed a significant correlation was demonstrated between
the pre-treatment yield of yeast colonies by cultivation
and the therapeutic effect of nystatin32 .
The denture has been cited as an important source of
re-infection32'187. In the study by Olsen187 a number
of treatment combinations were tested. Sucking
amphotericin lozenges with the dentures out caused a
significant reduction in the number of Candida colonies
derived from the palate but, not surprisingly, the
candidal colonisation of the denture fitting surface was
relatively unaffected. It was necessary to soak the
dentures in chlorhexidine to bring about a reduction in
yeasts at this site. Clearly antimicrobial therapy
needs to be directed at both the oral mucosa and the
denture base. Resistance of yeasts to antifungal agents
could be an explanation for failure of therapy in some
cases. Ritchie et al27 claim to have demonstrated
resistance of yeasts to both amphotericin and nystatin
in vitro. However Martin et al186 tested C.albicans
isolates from 500 cases of chronic atrophic candidosis
and found no resistance to nystatin. They concluded that
poor patient compliance was a more likely explanation for
failure of antifungal treatment. Other factors which
might be associated with relapse and recurrence have
remained largely uninvestigated. Bergendal183 followed
up patients one year after treatment with either a
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combination of nvstatin and new dentures or new dentures
alone. Nystatin treatment conferred no long term
benefits. Since all patients were provided with new
dentures the effect of trauma is difficult to assess.
Persistent erythema was significantly associated with
plaque and yeasts on the denture fitting surface.
Antifungal treatment has been shown to improve or resolve
subjective symptoms15'29'32 and other oral
conditions17'29'32 associated with denture stomatitis.
It has also been shown to lead to reversal of
the histopathologic161 and immunologic173 changes
seen in the condition. Nystatin will apparently inhibit
the growth of some streptococci isolated from denture
stomatitis lesions104 which may clearly be of benefit.
Antifungal drugs have been delivered to the mouth in some
novel vehicles. Amphotericin included in denture fixative
was ineffective188, whereas a soft lining material
incorporating nystatin seemed to be efficacious in the
treatment of denture stomatitis184. Such means of
applying antifungal agents might be effective in




Topical miconazole gel applied to the fitting surface of
the maxillary denture was effective in reducing erythema
in denture stomatitis and this was accompanied by
decreased candidal colonisation of various oral sites, as
judged by an imprint culture technique189. The drug is
also effective against some bacteria making it useful for
the treatment of angular cheilitis189. Miconazole has
been incorporated into a sustained drug delivery device
in the maxillary denture190, and half the patients so
treated were cured. The half who were not cured had high
initial levels of candidal colonisation and predisposing
systemic factors could also be identified in these
patients.
A systemic antifungal agent would have the potential
benefit of improved patient compliance with treatment and
also clearance of yeasts from endogenous sites which
might be a source of re-infection. Systemically
administered ketoconazole has been reported to be
effective in the treatment of denture stomatitis in one
patient191. However the use of this drug may be
associated with serious side effects192. A more
promising drug in this area is the recently introduced
bis-triazole, fluconazole. Fluconazole is very well
absorbed via the oral route and is widely distributed
throughout body fluids, including saliva, having an
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elimination half life of 30 hours193. The activity of
fluconazole and ketoconazole against Candida albicans
has been compared194. Whilst fluconazole was 16-fold
less active than ketoconazole when tested in vitro it
was 20-fold more active than ketoconazole in vivo. This
remarkable finding was assumed to be due to differences
in distribution and metabolism between the two drugs. The
efficacy of fluconazole has been demonstrated in
superficial fungal infections such as vaginal
candidosis195 and in oropharyngeal candidosis in
patients who are HIV positive196'197. Lamey et al198
described the successful use of fluconazole to treat a
single patient with chronic hyperplastic candidosis. As
well as being an effective antifungal agent it would
appear that fluconazole may also reduce the adherence of
Candida species to human buccal epithelial cells199.
Fluconazole has been shown to be efficacious in the
treatment of denture stomatitis in one open,
noncomparative study200 and in one placebo-controlled
trial13. In this latter study fluconazole was shown to
be a well tolerated and safe drug. One daily 50mg capsule
of fluconazole proved effective in reducing palatal
erythema and decreasing yeast colonisation. Clinically,
only 16% of patients were cured whilst 73% were
considered improved. In only three of 19 patients were
yeasts completely eradicated. Four weeks after
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completion of treatment clinical and mycologic relapse
had occurred in the majority of patients. Fluconazole
treatment resulted in marked qualitative changes in the
yeast flora although there was no obvious correlation
between the mycologic and clinical events. The patients
were given no instructions with respect to denture
hygiene or nocturnal denture wearing. It would be
interesting to see if, in the presence of good denture
hygiene, recurrence rates differed after treatment with
fluconazole compared with a topical antifungal agent. The
influence of re-infection from endogenous sites might
then be determined.
(b) Denture plaque control.
Walker et al10 demonstrated that the brushing of
dentures was effective in reducing inflammation in
denture stomatitis and that the use of amphotericin and
Steradent(R) conferred no additional benefit. The
patients had received instruction in denture brushing
techniques. Schou et al51 found no relationship between
the frequency of brushing and the amount of denture
plaque. Others found no relationship between the
frequency of denture brushing and the prevalence of
denture stomatitis105'106. Clearly the important factor
in denture brushing is not how often, but how well, it is
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done. For patients who lack manual dexterity or
motivation, chemical soaking agents may be more
appropriate. There are many such agents on the market and
the commonest consist essentially of alkaline
hypochlorite or alkaline peroxide201. They would all
appear to be effective to some degree201-202 but there
is relatively little information on which to base
comparisons201. Part of the beneficial effect of
denture soaking agents is that the dentures are left out
for a period of time.
An assumption that the matrix of denture plaque is
similar to that of dental plaque, consisting largely of
mutan, dextran and salivary glycoprotein, has led to
interest in the use of enzymes as denture
cleansers203-205. Enzymes, which might disrupt the
plaque matrix, would appear to be effective in removing
plaque from dentures203-205 and in reducing its
formation, particularly when combined with denture
brushing204. The effect of more efficient plaque
removal, when compared with the commercial cleanser
Steradent(R), was to produce an improvement in the
clinical condition of the mucosa in patients with denture
stomatitis203. Acids have also been used to clean
dentures with some success201-206.
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Brushing of the denture bearing tissues would appear to
be effective in reducing inflammation in denture
stomatitis42-207, especially if the dentures are also
removed at night42. Chamberlain et al207 found that
both tissue and denture brushing could reduce palatal
inflammation. However tissue brushing seemed to be
accompanied by an increase in denture plaque scores
whilst denture brushing failed to reduce denture plaque.
No explanation for this rather curious result was offered
and it is difficult to understand how denture brushing
brought about an improvement in the clinical condition
if not through a reduction in denture plaque.
Glazing of the denture fitting surface was effective in
reducing plaque formation and reducing palatal erythema
in patients with denture stomatitis208. Unfortunately
the glazing system tested does not appear to be
particularly durable. Stafford et al209 showed that if
dentures were left to dry for a period of eight hours
candidal colonisation of the fitting surface was
significantly reduced. The common practice of soaking the
dentures in water actually caused an increase in
colonisation. The dimensional changes in the dentures,
caused by drying, were so small as to be clinically
insignificant.
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Finally, in a study to evaluate an educational programme
designed to improve oral hygiene behaviour amongst
institutionalised elderly, it was found that the
programme had little effect on any of the variables
studied and that only about half the residents remembered
the programme two months after its termination210. The
conclusion drawn was that only well and not confused
elderly could benefit from such programmes and that
confused elderly required regular professional support
with oral hygiene.
(c) Disinfectants.
Chlorhexidine has been used as both a denture
disinfectant and a topical medicament29•187■211_214 . In
both types of application it has been shown to
significantly reduce clinical signs of
inflammation in patients with denture
stomatitis29'212'213 and to reduce yeast colonisation
of the palate and denture187'212*213. However when use
of chlorhexidine was terminated recurrence of
inflammation and increased yeast colonisation soon
followed in almost all patients29'187'212'213.
Prolonged use of a 0.2% chlorhexidine solution as an
overnight denture soaking agent prevented both clinical
and mycologic relapse214. After five months,dentures
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which had been soaked in this solution had accumulated
heavy staining. This staining could be removed using a
0.6% solution of alkaline hypochlorite. The potential
consequences of longer term use of chlorhexidine in these
circumstances remain unknown. Brushing of dentures with a
1% chlorhexidine gel was more effective in preventing
plaque formation than a commercial alkaline peroxide
soaking agent, but no more effective than brushing with a
placebo gel211. Chlorhexidine has been tested in
combination with amphotericin, when it would appear to be
effective29-187 , but in vitro testing has indicated
that combining nystatin and chlorhexidine reduces the
anti-candidal effect of both agents, possibly as a result
of salt formation215. One way in which chlorhexidine
may exert a beneficial effect is by reducing the adhesion
of Candida species to acrylic resin216.
Listerine antiseptic used as a mouthrinse and denture
soaking agent was found to be as effective as a denture
soft reline217 and nystatin218 in reducing
inflammation in patients with denture stomatitis.
Listerine was also effective in reducing yeast
colonisation218 although plaque scores were not
reduced217-218. In neither of these studies were
patients assessed after cessation of treatment and
relapse may well have occurred.
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(d) Prosthodontic treatment.
Long term resolution of denture stomatitis has been
demonstrated following occlusal equilibration of complete
dentures22. Also the use of tissue conditioning
materials32'219*220 and hard laboratory relines219
has been shown to reduce the severity of, and in some
cases resolve, palatal inflammation in patients with
denture stomatitis. Some studies of tissue conditioning
materials have not included long term follow-up
examinations, neither have they involved assessment of
denture plaque or yeast colonisation. This is important
since changing the nature of the denture fitting surface
may radically alter the ability of Candida to colonise
it. In the study by Budtz-Jorgensen and Bertram32 the
benefit of tissue conditioning was most pronounced in the
group of patients without verifiable Candida infection
prior to the start of treatment. The criterion used for
diagnosis of Candida infection was the presence of
hyphae in palatal smears. Patients who did have a
verifiable infection prior to treatment commencing
responded poorly to tissue conditioning. In neither group
of patients was the number of yeast colonies isolated by
cultivation significantly changed by treatment. Patients
who had hyphae present in palatal smears before treatment
continued to have hyphae present after treatment.
Unfortunately both smears and samples for cultivation
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were obtained from the palatal mucosa and not the denture
fitting surface, which might have been more interesting.
Also in this study, in a number of patients with
generalised inflammation who were treated with an
antifungal drug, localised areas of erythema persisted
after treatment. These patients were judged to have
traumatising dentures and the observations support the
contention that candidal infection is superimposed on
traumatic lesions.
Permanent soft relining materials, such as
Molloplast(R), may be used in the management of chronic
soreness beneath mandibular dentures in particular221.
Such soft lining materials may be associated with
increased yeast colonisation83'222. An increased
incidence of denture stomatitis has been reported in
association with soft linings221. In contrast Wright et
al223 found no increased incidence of inflammation of




Patients with the granular form of denture stomatitis may
have the degree of erythema reduced by antifungal therapy
but the papillary hyperplasia remains unaffected by such
treatment32. Furthermore biopsies of these lesions show
persistence of sub-epithelial inflammation following
antifungal treatment161, probably due to the presence
of microbial plaque and debris in the deep epithelial
crypts18. These patients may require surgery to resect
the hyperplastic tissue224-225. Surgical treatment
would appear to result in acceptable long term reduction




Denture stomatitis is a relatively minor condition. It
is, however, common and may occasionally give rise to
significant discomfort. The evidence suggests that
overgrowth of yeasts on the denture fitting surface is
strongly implicated in the aetiology, although many
studies have involved only semi-quantitative estimation
of yeast density. Increased yeast colonisation appears to
be directly related to increased amounts of denture
plaque and both are related to increased severity of
mucosal inflammation. Bacteria are far more numerous in
denture plaque than yeasts but their role has rarely been
investigated. The possibility exists that the pathogenic
effect of denture plaque is non-specific and not related
to any one particular organism. There is certainly
evidence to suggest that poor denture hygiene is
associated with the condition and that improved hygiene
may lead to its resolution. It is surprising that no one
has conducted denture hygiene withdrawal studies similar
to those which established the causal relationship
between plaque and gingivitis226 .
In favour of the specific effects of yeasts are studies
showing a significant relationship between increased
numbers of Candida and more severe histologic signs of
- 71 -
inflammation. The same would not appear to be true of
bacteria. Of course proof of association between
Candida and denture stomatitis is not proof that
Candida is the cause. Further supporting evidence for
the role of Candida comes from the knowledge that
denture stomatitis is improved by antifungal therapy and
that a very similar condition can be induced in animals
by inoculation of yeasts beneath palatal plates.
Whilst few, if any, studies could be described as
conclusive, the body of evidence seems to favour
Candida as a major causative factor. However Candida
has been investigated far more frequently than any other
single factor and this may give a very misleading
impression.
Trauma from dentures is difficult to assess objectively.
This may partly explain why the evidence in support of a
contributory role for trauma in the aetiology of denture
stomatitis presents certain problems. The patchy form of
erythema appears to be associated with traumatic dentures
and has been shown to resolve following prosthetic
treatment alone. However the patches of erythema are
topographically related to areas of candidal
colonisation. In addition, when Candida was inoculated
beneath palatal plates in rats, the induced inflammation
was initially patchy and later diffuse. The inference
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which may be drawn is that the patchy form of erythema
may simply be a less severe form of candidal infection.
It has been suggested that yeasts may colonise initially
in the region of traumatic lesions. Adherence of
Candida could be aided by the presence of inflammatory
exudate and subsequently candidal toxins and antigenic
components would more easily pass through the more
permeable epithelial barrier. This is speculation.
The logical question which remains unanswered is why, if
instability and occlusal overloading are important
aetiological factors, is denture stomatitis so rare in
the mandibular mucosa? A denture may be traumatic by
being occlusive and preventing ingress of saliva. The
protective effect of saliva is well recognised.
Unfortunately there is very little direct evidence to
support this view. There is evidence to suggest that the
environment beneath the maxillary denture supports the
growth of yeasts and of one Candida albicans serotype
in particular.
A number of host related factors have been implicated in
denture stomatitis but few would appear to be of major
significance. The evidence relating to denture wearing
habits is inconclusive. Few studies have looked at
nocturnal denture wearing in combination with denture
hygiene. It would seem logical to assume that constant
- 73 -
denture wearing in the presence of excellent denture
hygiene would have little deleterious effect, whilst in
combination with poor hygiene it could lead to more
severe inflammation. There is evidence that severe
inflammation does occur more frequently in those who wear
their dentures both day and night. Increased intake of
dietary sugars would appear to increase candidal
colonisation and lead to more pronounced mucosal
inf1ammation.
Chemical irritation and allergy may be responsible for
inflammation beneath dentures but both are rare and the
clincal presentation would appear to be distinctive.
With regard to treatment, simple plaque removal appears
to be effective. The major problem with antifungal
treatment is the recurrence of the condition which occurs
after treatment ceases. It seems to be difficult to
clear Candida, even from the oral cavity, with topical
agents. Compliance with tedious and prolonged regimens
may be one reason for this. Also topical agents would
have minimal, if any, effect on candidal colonisation at
other host sites which may be a source of re-inoculation
for the mouth. Whilst the results of antifungal therapy
have been disappointing, many of the agents tested have
had limitations.
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Although recurrence has often been commented upon it has
rarely been investigated in any depth. For instance the
effect of antifungal treatment on different Candida
species has hardly been mentioned and similarly the role
of prosthetic factors in relation to recurrence has
received scant attention.
The immunology of denture stomatitis remains poorly
understood, not least because much of the experimental
evidence is contradictory. This may be partly explained
by the fact that many different methods have been
employed. Surprisingly the role of the secretory immune






The aims of the research presented in this thesis were:
1. To determine the efficacy of a recently introduced
systemic antifungal agent (fluconazole) in comparison
with an existing topical agent (amphotericin), with
respect to palatal erythema and subjective symptoms.
2. To examine the relative rates of relapse and
recurrence following each treatment, using the same
clinical variables.
3. To determine the safety of and tolerance to the drugs.
4. To examine the mycologic effects of each drug as
determined by the isolation of yeasts from a number of
oral sites, quantitation of yeast organisms present in
the mouth and the differential effects on yeast
species.
5. To determine the effects of a number of patient and
prosthodontic variables on the outcome of antifungal
treatment of denture stomatits.
6. To examine the effect of antifungal treatment on the
humoral immune response.
7. To conduct a preliminary study of the cellular immune
response in patients with denture stomatitis.
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PATIENTS
Patients were selected from those attending the
prosthetics department of Edinburgh Dental Hospital.
Those patients who were over 16 years of age and who
presented with a clinical diagnosis of denture stomatitis
were admitted to the study after explanation and consent.
Patients were excluded from the study on the basis of one
or more of the following:
1. The presence of oral disease other than denture
stomatitis or candidosis which might be associated
with the wearing of dentures.
2. Female patients who were either a) pregnant or
b) lactating or c) of child bearing age and not using
reliable contraception.
3. Known impairment of renal or hepatic function.
4. Use of any other antifungal treatment during the
previous 10 days.
5. Use of barbiturates, coumarin anticoagulants or oral
hypoglycaemic agents.
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6. Known sensitivity to polyenes or the azole group of
antimycotics, including imidazoles and triazoles.
7. Intention by the patient to donate blood during and/or
for three weeks after the study medication period.
8. A history of alcoholism, drug abuse, psychosis,
antagonistic personality, poor motivation or other
emotional or intellectual problems likely to
invalidate informed consent, or limit the ability of
the subject to comply with protocol requirements.
9. Participation by the patient in any other study
involving investigational or marketed drugs during the
previous month or intention of doing so during the
study.
Fifty nine patients were recruited. Of these 16 were male
with a mean age of 51 years (range, 22 to 77 years) and







At the initial visit patients were assessed clinically
and mycologically, and blood was obtained for
heamatologic and immunologic investigations. All
information was recorded on a printed form and these were
kept in a seperate file for each patient. Patients were
then assigned to receive either fluconazole or
amphotericin according to a pre-determined randomization
list. Fluconazole was taken as a 50mg capsule, once a
day, for 14 days. Amphotericin was administered in the
form of lozenges which were to be allowed to dissolve in
the mouth with the dentures removed, plus amphotericin
cream which was to be applied to the fitting surface of
the upper denture. The lozenges were to be sucked four
times a day and the cream applied before the denture was
replaced in the mouth, after sucking the lozenge. The
amphotericin regimen was to be continued for 28 days. All
patients received instruction in denture hygiene, which
was to include soaking in a hypochlorite solution plus
brushing with a commercial denture paste at least once a
day. Patients were advised to leave their dentures out at
night.
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Patients were reviewed at one week, four weeks, and
twelve weeks after treatment commenced. The same
clinician examined all patients at all visits and was
unaware of the medication prescribed.
2. First Visit
The initial visit consisted of a detailed assessment as
follows:





(a) Patient Basic Data and History




day, grams tobacco per week
(iii) Alcohol consumption.
(iv) History of denture stomatitis:
duration of present episode, previous episodes.
(v) Previous treatment for denture stomatitis:
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drug, dose, date started, date stopped, efficacy.
(vi) Relevant concomitant medical conditions, duration.
(vii) Concomitant drug therapy, dose, duration.
(b) Dental Assessment
(i) Dentures:
Upper - complete/partial, date acquired.
Lower - complete/partial, date acquired.
(ii) Assessment of dentures:







The occlusal vertical dimension was recorded as either
correct, increased or decreased, whilst all other
factors were recorded as good, fair or poor.
Examination of the dentures was based on the method
described in a standard text on prosthetic
dentistry227, with modifications. Assessment of
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retention, stability, extension and hygiene was confined
to the upper denture only. Assessment of occlusion and
vertical dimension obviously required the examination of
both dentures together.
Retention of complete dentures was tested by grasping
the incisor teeth and attempting to pull the denture away
from the tissues. A similar attempt was made to dislodge
partial dentures using whichever artificial teeth were
present.
Stability of complete dentures was tested by placing
the index fingers on the occlusal surfaces of the upper
premolar teeth and attempting to move the denture
laterally, antero-posteriorly and rotationally. A similar
attempt was made to move partial dentures using the
saddles present. The tendency of partial dentures to rock
when finger pressure was applied to the occlusal surfaces
of individual saddles was also included in the assessment
where appropriate.
It was relatively straightforward for a single examiner
(the author) to grade retention and stability on a three
point scale, namely, good, fair or poor.
Extension of the denture base was assessed in
relation to the full denture bearing area. This was more
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important in relation to complete dentures and obviously
may have had an influence on retention and stability.
However full extension is also important in relation to
denture support. Where partial dentures were worn
assessment of extension involved a judgement as to what
degree of extension of the saddles, or major connector,
was required in terms of design. Correct extension was
recorded as good, moderate over or under-extension as
fair, and gross over or under-extension as poor.
Occlusion of complete dentures was assessed in the
retruded position and in excursive movements. It was
graded as follows:
good - balanced occlusion and articulation,
fair - balanced occlusion but unbalanced articulation,
poor - unbalanced occlusion and articulation.
Where partial dentures were worn the assessment depended
on whether or not an acceptable intercuspal position
(ICP) was indicated by the patient's natural teeth. Where
there was no acceptable ICP the assessment was similar to
that described for complete dentures. Otherwise they were
graded as follows:
good - conform to ICP, provide contacts with opposing
artificial and/or natural teeth and do not interfere with
excursions,
fair - conform to ICP, do not provide adequate contacts
and interfere with excursions,
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poor - do not conform to ICP, or provide adequate
contacts, and interfere with excursive movements.
No description can include every possible situation which
might be encountered. The general strategy was to grade
the occlusion according to its potential to traumatise
the denture bearing mucosa. Assessment of occlusion was
obviously not applicable to edentulous patients who wore
no lower denture.
Hygiene was assessed by examining the fitting
surface of the upper denture for the presence of
visible deposits of plaque. No deposits were graded as
good, light to moderate deposits as fair, and gross
deposits as poor.
Occlusal vertical dimension was assessed by
measuring the freeway space with the patient seated
upright. A Willis gauge was used for this purpose and
multiple measurements obtained until consistent readings
were achieved. A freeway space of 3-4mm was taken to
indicate a correct occlusal vertical dimension, whilst a
lesser or absent freeway space indicated an increased
dimension, and a greater freeway space indicated a
reduced dimension. It was occasionally neccessary to
confirm the findings by observation of facial proportions
and the closest speaking space. Assessment of vertical
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dimension was not applicabl
wore no lower denture or to
where the vertical dimension
natural teeth.
e to edentulous patients who
some partial denture wearers
was wholly determined by the
(iii) The number and position of the teeth present were
recorded.
(c) Clinical Assessment
(i) Denture stomatitis was classified as:
Localised erythematous - patchy areas of erythema,
not including pin-point hyperaemia alone.
Diffuse erythematous - erythema covering the whole of
the denture bearing area.
Hyperplastic/granular - either of the above types of
erythema with superimposed papillary hyperplasia.
(ii) Subjective symptoms of pain, burning sensations,
abnormal tastes and dry mouth were recorded as absent,
mild, moderate or severe
- 87 -










Samples for the cultivation of yeasts were obtained by
vigorously swabbing the:
Hard palate
Fitting surface of the upper denture
Dorsum of the tongue
Floor of the mouth
Skin of left angle of the mouth
Skin of right angle of the mouth
An oral rinse sample was obtained to allow quantitation
of yeasts228. The patient was asked to rinse the mouth
for one minute with 10ml of phosphate buffered saline and
then to return the solution to the container provided.
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(e) Blood Samples
Approximately 35ml of venous blood was obtained for
haematology, blood chemistry and estimation of total and
specific anti-candidal serum immunoglobulins. Details of
these investigations may be found in the chapter on
laboratory methods.
3. Review Visits - Week One and Week Four
(a) Concomitant Conditions and Treatment
Any changes in concomitant
therapy were noted, including
these changes.
medical conditions or drug
the timing and duration of
(b) Adverse Events
The patient was questioned as to the occurrence of any
adverse events which might have been associated with the
trial medication. The nature of any adverse event was
recorded as follows:
Adverse event - specify




Attributable to study treatment - yes, no




study treatment temporarily suspended
study treatment stopped
(c) Clinical Assessments
Denture stomatitis, if present, was classified in the
same way as at the initial visit. A change from diffuse
erythematous to localised erythematous would have been
indicative of improvement. Where no such change was
observed any marked reduction in erythema, in comparison
with the baseline visit, was recorded.
The patient was again questioned as to the subjective
symptoms of pain, burning sensations, abnormal tastes and
dry mouth, which were recorded as absent, mild, moderate
or severe. The same variants of oral candidosis as on the
first visit, were recorded as present or absent.
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(d) Mycologic and Blood Samples
The samples taken for mycologic investigation at the
baseline visit were repeated at week one and week four,
as were the blood samples for haematology, blood
chemistry and immunology.
4. Final Review - Week Twelve
This visit was approximately eight weeks after the
completion of amphotericin therapy and ten weeks after
the completion of fluconazole therapy. Review visits were
designed to be equi-distant from the start of treatment
rather than from its completion.
Changes in concomitant medical conditions and therapy
were again noted as was the persistence of any adverse
effects. Clincal and mycologic assessments were repeated
and blood was obtained for immunologic investigation.
Haematology and blood chemistry were not repeated at this
visit (see Laboratory Methods).
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5. StatisticaL Methods
Parametric data were analysed using the t test for sample
means and the chi-square test for proportions. It should
be noted that in the chi-square tests expected
frequencies were occasionally low. Non-parametric data
were compared using the Mann-Whitney and Wilcoxon rank
sum tests.
Comment on Clinical Methods
Assessment of denture quality by grading a number of
factors as good, fair or poor may be considered
subjective and crude. Other studies have involved
similar means of denture assessment and used similar
gradations22'46'109'110'229'230. The three point scale
of good, fair and poor seemed appropriate since this is
the type of evaluation frequently used in clinical
practice. Further gradations would imply a false level of
precision. Similar methods of assessing denture hygiene
have also been used in other studies46'51'231. The
problems associated with subjectivity can be limited in
two ways. Firstly, one operator can be responsible for
assessing all patients. The judgments remain subjective
but they should be consistent and, if the operator is
unaware of the treatment prescribed, there is no reason
to assume bias. Secondly, more than one operator can
- 92 -
assess each patient and the results compared. The problem
with this method is how to arrive at an average between,
for instance, "good" and "fair"? The first method was the
one chosen for this study, with the author being
responsible for the assessment of all patients.
In the diagnosis and classification of denture
stomatitis, pin-point hyperaemia which might be
attributable to traumatic occlusion of salivary gland
duct orifices, was deliberately excluded if it presented
as the only clinical sign.
With the oral rinse sample there was a dilemma as to
whether the patient should wear the dentures whilst
rinsing. There are no data available to suggest how this
variable affects the resultant colony count. Rinsing was
generally performed with the dentures removed but some
patients found themselves unable to expectorate without
their dentures in place. These patients were allowed to
rinse whilst wearing their dentures. Comparison of colony
counts between patients is therefore not possible.
However, the important consideration is the change in the
quantitiy of oral yeast in each individual patient during
the course of the study. This is determinable from the
data since patients were consistent in either wearing or
not wearing their dentures whilst rinsing, throughout the
study.
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Denture hygiene was assessed at the initial visit only.
This caused difficulties, in that it was not possible to
assess to what degree hygiene improved over the course of
the study, or the way in which this influenced clinical
outcome (vide infra).
Assessment of palatal erythema again presents problems of
subjectivity and consistency over the study period. At
review visits, absence of erythema would clearly
represent improvement, indeed the patient could be said
to be cured. Reduction in the erythematous area, from
generalised diffuse to patchy, could also be regarded as
an improvement. Difficulties arise where the erythematous
area remains the same but the degree of erythema changes.
In the original protocol this problem was not
anticipated but it soon became apparent that significant
changes in the degree of erythema, from one visit to the
next, would need to be recorded.
Previous studies have rated palatal erythema using scales
such as: absent, slight, moderate or
severe1 3,29,182,185,186,217 t However the assessment
remains subjective. The following scale was used by De
Paola et al217:
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0 Normal - Tissue has pink colour with stippling and
texture that are considered healthy.
1 Mild - Slight erythema, no swelling or oedema, normal
size and shape.
2 Moderate - Erythema with some oedema, loss of stippling
and slight change from normal shape.
3 Severe - Acutely inflamed, erythema, oedema, definite
changes in size, shape and consistency, hyperplastic
projections.
The number of factors in each grade makes for difficulty
in interpretation. For instance in grade 3 (severe), what
is to be made of "acutely inflamed", and are hyperplastic
projections absolutely neccessary for an award of grade
3? There is still the problem of ensuring that judgments
remain consistent throughout the study. This has been
addressed by photographing the palate at each visit and
observing the prints in sequence at the end of the
study12'13-29-212. This requires carefully standardised
techniques for exposure and processing of the film. An
error in either could render the results impossible to
interpret. Again the problem of subjectivity remains.
Given the difficulties described it seems defensible to
suggest that an experienced clinician could assess the
degree of erythema in the same way as he would in
a clinical situation. An assessment of absent, marked
improvement or unchanged, would then be appropriate. This
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was the method adopted in the present study. Although 59
patients were involved they were seen over a period of
more than a year. The fact that at any one time a
relatively small number of patients were taking part in
the trial, made this form of assessment possible. With
regard to symptoms, self grading by the patient, using a
scale of absent, mild, moderate or severe, is acceptable
clinical methodology232.
Some clinicians may be of the view that diabetes can
influence the clinical presentation of oral candidosis.
In this study diabetic patients were not necessarily
excluded unless they were taking oral hypoglycaemics,
which may have interacted with fluconazole. Blood sugar
levels were not estimated and the possible influence of
defective glucose metabolism cannot, therefore, be
determined from this study. This issue has been
specifically addressed in the past, although with no





1 . Mycologic Samples
Swabs were transported immediately to the laboratory
where they were placed in Sabouraud's broth and incubated
for 48 hours, prior to plating out on Sabouraud's
dextrose agar. After a further 48 hours the yeasts were
speciated using a commercially available analytical
profile index (API) system ( La Balme les Grottes, 38390
Montalieu Vercieu, France ), which permits speciation of
yeasts on the basis of their ability to utilise
specific substrate sources for growth233'234. Details
of the method may be found in Appendix 3.
The oral rinse samples were centrifuged at 1700 x g for
10 minutes and the deposit resuspended in 1ml of sterile
phosphate buffered saline. An aliquot of the concentrated
rinse sample was inoculated onto and spread over a
Sabouraud's dextrose agar plate which was incubated for
48 hours. The number of yeast colonies were then counted




The purpose of the haematologic investigations was to
establish the presence of any deficiency which might be
contributing to the clinical condition and monitor any
changes over the treatment period which might be
attributable to the trial medication. The following
estimations were carried out in the Haematology
Department, Royal Infirmary of Edinburgh:
Normal Range
Male Female
Haemoglobin g/dl 13.00 - 18.00 11 . 50 - 16.50
Haematocrit ratio 0.40- 0.54 0 .37 - 0.47
Red Blood Cells xl012/l 4.50- 6.50 3 . 80 - 5.80
Platelets xl09/l 150 - 350 150 - 350
White Blood Cells xl09/l 4.00 - 11.00 4.00 - 11.00
Neutrophils % 40 -- 75
Lymohocytes % 20 -- 45
Monocytes % 2 -- 10
Eosinophils % 1 -- 6
Basophils % Less than 1
Serum B12 ng/1 170 -- 1600
Serum Folate ug/1 2.2-- 18.0
ESR mm/hr 1 - 10 3 -■ 15
Serum vitamin B12 and serum folate were estimated at the
first visit only.
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3. Liver Function Tests
Because of the potential for certain azole drugs to
induce hepatotoxicity, liver function tests were
performed on all patients during the period of active
medication. The following tests were performed in the




Bilirubin umol/1 2 - 17
Alanine Aminotransferase units/1 10 - 40
Alkaline Phosphatase Units/1 40 - 100
Gamma Glutamyl Transferase Units/1 10-55 5-35
Total Protein g/1 60 - 80
Albumin g/1 36 - 47
Aspartate Aminotransferase Units/1 10 - 35
Estimation of serum ferritin was also performed in the
Department of Clinical Chemistry ( normal range, male: 16
350 ug/1, female: 8 - 300 ug/1 ). This was again
related to the possibility of a deficiency state
contributing to the clinical condition and was performed
only at the initial visit.
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4. Immunology
Total and specific anti-candidal antibody levels were
measured in serum and saliva using the techniques
described below. Serum was derived from 10ml of venous
blood obtained from each patient at each visit.
Approximately 5ml of whole saliva was also collected
by expectoration, salivary flow being unstimulated.
(a) Radial Immunodiffusion
Total isotype specific serum and salivary immunoglobulin
levels were estimated in duplicate, using a commercially
available single radial immunodiffusion system (Behring,
Marburg, Germany). This technique involves the placing of
test samples into wells in plates of agarose gel
containing antiserum to human IgG, IgA or IgM. Antibody
in the test sample diffuses outwards into the gel until
the point of antibody - antigen equivalence is reached,
when a precipitin ring is formed. Using standard sera a
standard curve can be constructed in terms of the
diameter of the precipitin ring against the known
immunoglobulin concentration. The immunoglobulin
concentration of the test samples can then be determined
by reference to this curve235-236. Standard reference
sera of known IgG, IgM and IgA concentration was donated
by the Blood Transfusion Service, Edinburgh.
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(b) Enzyme-Linked Immunosorbent Assay (ELISA)
Class specific anti-candidal antibody levels were
measured on two seperate occasions, in triplicate, using
an ELISA developed in the Oral Pathology laboratory
at the University of Edinburgh175. A description of the
reagents used may be found in Appendix 1.
Polystyrene flat bottom 96 well microtitre plates
(Flow Laboratories, Rickmansworth UK) were sensitised
overnight at four degrees centigrade with whole Candida,
albicans in bicarbonate buffer at pH 9.6. The plates
were then coated with test samples of serum or saliva in
a volume of lOOul for 90 minutes. These test sarnies were
diluted in PBS-tween containing 1% foetal calf serum
(Flow Laboratories, Rickmansworth, UK). Serum dilutions
of 1:8100 were used for IgG and IgM estimation and 1:2700
for IgA estimation. Saliva dilutions of 1:3 were used for
estimation of IgG and IgM, and 1:9 for IgA estimation. A
reference serum consisting of pooled sera from 10
patients and 10 controls was used in each plate in serial
dilutions from 1:1000 to 1:24,300 for serum
immunoglobulin estimation, and from 1:33,000 to
1:8,100,000 for salivary immunoglobulin estimation.
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The plates were then coated with lOOul of goat anti-human
alkaline phosphatase conjugated IgG, IgA or IgM (Sigma,
Poole, Dorset, UK) diluted to 1:1000 in PBS-tween
containing 1% foetal calf serum for 90 minutes. Plates
were washed three times between stages with PBS-tween and
tapped dry. Finally the wells were filled with
p-nitrophenyl phosphate (Sigma, Poole, Dorset, UK) lmg/ml
in diethanolamine buffer. The rate of substrate
degradation was indicated by the colour change which is
proportional to the antibody concentration in the
samples. The absorbance of the yellow colour produced by
the reaction of the enzyme with p-nitrophenyl phosphate
was read at 405 nanometres in a Titerek Multiscanner
(Flow Laboratories, Rickmansworth, UK) after one hour.
The optical density was assessed using commercially
available computer software (Flow Laboratories,
Rickmansworth, UK) and correlated with the reference sera
which were arbitrarily assigned to contain 100 ELISA
units of IgG, IgA and IgM. Serum and salivary
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1. Patients
Of the 59 patients entered into the study, 29 ( 8 males,
21 females) were randomly selected to receive fluconazole
and 30 (8 males, 22 females) to receive amphotericin. The
average age of fluconazole patients was 50 years and that
of amphotericin patients was 60 years. About half the
fluconazole patients and one third of amphotericin
patients were smokers. Alcohol consumption was apparently
low in both groups. Demographic details are summarised in
Tables 4 and 5, and smoking status in Table 6.




















































































































Very few patients had significant concomitant medical
conditions. Only two patients in each treatment group
were receiving other drug therapy, with one amphotericin
patient receiving six additional medications. Only one
patient, whose trial drug was fluconazole, began
concomitant non-study medication during the trial.
2. Dental Assessment
Of the 59 patients entered into the trial 33 were
edentulous in the maxilla. There were 19 such patients in
the amphotericin group and 14 in the fluconazole group.
The denture wearing status in shown in Table 7.
TABLE 7: TYPE OF DENTURE WORN
Fluconazole Amphotericin Both Groups
CU/CL 8 13 21
CU/PL 0 4 4
cu/~ 6 2 8
PU/PL 4 1 5
PU/- 11 10 21
CU=complete upper, CL=complete lower, PU=partial
PL=partial lower, -=no lower denture.
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The age of the dentures was, in many cases, an
approximation. Thirteen patients were unable to estimate
the age of their dentures. For both treatment groups, the
patients had been wearing their existing dentures for an
average of 9 to 10 years, the minumum being less than one
year and the maximum being more than 40 years.
The quality of the dentures being worn is indicated by
the data in Tables 8 to 13.
TABLE 8: DENTURE QUALITY - RETENTION
Fluconazole Amphotericin Both Groups
Good 7 8 15
Fair 10 10 20
Poor 12 12 24
Total 29 30 59
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TABLE 9: DENTURE QUALITY - STABILITY

















TABLE 10: DENTURE QUALITY - EXTENSION
Fluconazole Amphotericin Both Groups
Good 8 11 19
Fair 11 11 22
Poor 10 7 17
Total 29 29 58
(This assessment was considered not applicable for one
patient in the amphotericin group.)
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TABLE 11: DENTURE QUALITY - HYGIENE
Fluconazole Amphotericin Both Groups
Good 10 6 16
Fai r 15 17 32
Poor 4 7 11
Total 29 30 59
TABLE 12: DENTURE QUALITY - OCCLUSION
Fluconazole Amphotericin Both Groups
Good 10 7 17
Fair 6 9 15
Poor 12 11 23
Total 28 27 55
(This assessment was considered not applicable for one
patient in the fluconazole group and three patients in
the amphotericin group.)
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TABLE 13: DENTURE QUALITY - VERTICAL DIMENSION
Fluconazole Amphotericin Both Groups
Reduced 6 5 11
Correct 21 14 35
Increased 0 2 2
Total 27 21 48
(This assessment was considered not applicable for two
patients in the fluconazole group and nine patients in
the amphotericin group.)
There is very little difference between treatment groups
as far as the individual denture factors are concerned.
The information gathered can be presented in a different
manner, to indicate the overall quality of each patients
denture. For each patient, therefore, a score is given
for the denture factors of retention, stability,
extension, hygiene and occlusion: good = 1, fair = 2,
poor =3. A denture which was assessed as good for all
factors would score the minimum total of 5, whilst a
denture that was assessed as poor for all factors would
score the maximum total of 15. A score of 10 could be
said to represent a denture which was fair overall. A
summary of the scores obtained in this manner is shown in





in total, against the scores
numbers are displayed in





















Patients were excluded from this analysis if any
assessment was deemed to be inapplicable, as no score
could be given in such an instance. Vertical dimension
was not included in the scoring because of the number of
"not applicable" cases. It is apparent that the groups
are quite evenly matched as far as overall denture
quality is concerned. There are more dentures on the
poor side of fair than on the good side of fair. If both
groups are considered together exactly two thirds of
patients had dentures which scored 10 or more.
Summary: denture quality tended towards poor and this




The number of patients in each treatment group with each
classification of denture stomatitis at the initial
examination is given in Table 15.
TABLE 15: DENTURE STOMATITIS - CLASSIFICATION
Fluconazole Amphotericin
Localised Erythematous 7 7
Diffuse Erythematous 15 17
Hyperplastic/ granular 7 6
Total 29 30
The treatment groups were well matched in terms of the
frequency of each type of denture stomatitis. In
total, slightly more than one half of the patients had
the diffuse erythematous form of denture stomatitis. The
remaining patients were divided almost equally between
the localised and the hyperplastic form of the disease.
Only nine (5 fluconazole and 4 amphotericin) patients
were able to provide even a rough estimate of the
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duration of their present episode of denture stomatitis.
One patient in each group reported a previous episode of
denture stomatitis during the past year. Many patients
had no awareness of the condition.
There was a marked difference between smokers and
non-somkers with regard to the initial classification of
denture stomatitis. Overall there were 25 smokers and 27
non-smokers. Amongst smokers, the hyperplastic granular
form of denture stomatitis was the commonest. In fact, of
the 13 patients who had hyperplastic granular denture
stomatitis, 10 were smokers. Amongst the non-smokers the
diffuse erythematous form of denture stomatitis was the
most common. Twice as many non-smokers as smokers had
this form of the disease. The localised erythematous type
was equally distributed amongst smokers and non-smokers.
Nine patients in the fluconazole group and 10 in the
amphotericin group had been previously prescribed
antifungal drugs. Some patients had received more than
one drug in the past and a total of 28 previous
antifungal prescriptions were recorded. Twenty four of
these prescriptions were for polyenes, with amphotericin
and nystatin being equally popular.
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4. Baseline Symptoms
On questioning, thirty one patients (52.5%) complained of
subjective symptoms of either pain, burning sensations,
abnormal tastes or dry mouth, with 14 of these patients
complaining of more than one symptom. The commonest
complaint was of dry mouth (19 patients), followed by
burning sensations (15 patients), abnormal tastes (11
patients) and pain (7 patients). However the majority of
symptoms were reported to be mild. Table 16 lists the
number of patients with each symptom, according to
severity. Of the 31 symptomatic patients 16 were
subsequently assigned to receive fluconazole and 15 to
receive amphotericin.
TABLE 16: BASELINE SYMPTOMS
Absent Mild Moderate Severe
Pain 52 3 3 1
Burning Sensation 44 6 6 3
Abnormal Taste 48 6 3 2
Dry Mouth 40 13 3 3
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Of the 31 patients with symptoms, 17 had the diffuse
erythematous form of denture stomatitis, nine had the
hyperplastic form and five had the localised form.
Symptoms were therefore commonest amongst patients with
hyperplastic/granular denture stomatitis. Approximately
69% of this group of patients had symptoms compared with
approximately 53% of those with diffuse erythematous and
36% of those with localised erythematous denture
stomatitis.
5. Concomitant Oral Candidoses
Although the term concomitant oral candidoses is used,
the diagnosis was made on clinical grounds alone. At the
initial assessment there were no patients with acute
erythematous candidosis, median rhomboid glossitis or
chronic mucocutaneous candidosis. One patient had acute
psuedomembranous candidosis and two had chronic
hyperplastic candidosis. Eleven patients (18.6%) had
angular cheilitis which was bilateral in each case.
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6. Efficacy Analyses - Patient Evaluability
Although nine patients did not complete the study
according to the protocol, only three were excluded from
all efficacy analyses: two amphotericin patients for poor
compliance and one fluconazole patient who failed to
return after the baseline visit. One further amphotericin
patient had negative baseline mycology and was therefore
excluded from the mycologic analysis. However this
patient responded to treatment and was included in the
analysis of clinical efficacy. The most frequent protocol
violation was a failure to complete all vists. The timing
of the review vists is described in the trial design. In
practice there was some variance from this if patients
found it necessary to change appointment dates. Some
patients were excluded from tables and analyses for
particular visits because they attended outside the
defined window for that visit. The visit windows are
shown in Table 17. Essentially the visit windows were
designed to allow patients to be assessed during
treatment, after the completion of treatment and at a
long term follow-up.
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TABLE 17: VISIT WINDOWS
Days post baseline visit
Fluconazole Amphotericin
Visit
2 (On treatment) 6-14 6-27
3 (Off treatment) 15-42 28-42
4 (Long term follow-up) >42 >42
It should be stressed that most patients fell within
these limits and were assessed at the time anticipated in
the trial design.
7. Clinical Efficacy of Fluconazole and Amphotericin.
(i) Palatal Erythema
Since palatal erythema is the major clinical sign of
denture stomatitis this was used as the main indicator of
clinical efficacy. Table 18 shows the number of patients
in each group who were cured, improved or unchanged at
each visit. The chi-square test was used to compare the
two groups. There was no significant difference between
the two treatments at any visit. (Significance level p =
0.05)
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TABLE 18: CLINICAL EFFICACY
1 Week 4 Weeks 12 Weeks
F A F A F A
Cured 5 9 11 14 6 5
Improved 8 6 10 6 9 7
No Change 13 1 1 4 2 11 12
Total 26 26 25 22 26 24
(F=fluconazole, A=amphotericin, Cured, improved and no
change are in comparison with baseline assessment.)
The best clinical cure rate was seen at the four week
visit with approximately 44% of patients in the
fluconazole group cured and 63% in the amphotericin group
cured. If the categories cured and improved are combined
greater clinical efficacy is observed. Table 19 gives the
percentage number of patients in each group who were
either cured or improved at each visit, in comparison
with the baseline assessment.
TABLE 19: CURED OR IMPROVED
1 Week 4 Weeks 12 Weeks
Fluconazole 50% 84% 58%
0
Amphotericin 58% 91% 50%
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Both drugs had achieved their maximum observed efficacy
at the one month visit. At this visit the 95%
confidence limits are (70%,98%) for fluconazole and (79%,
100%) for amphotericin. It is therefore 95% certain that
the cure rate lies between 70% and 98% for fluconazole
and between 79% and 100% for amphotericin. By the time
of the long term follow-up there had clearly been
considerable relapse and recurrence, with figures for
patients cured or improved returning towards the level
seen after one week of treatment.
(ii ) Symptoms
At all visits patients were asked to grade the symptoms
pain, burning sensation, abnormal taste and dry mouth, as
absent, mild, moderate or severe. The results for each
symptom at each follow-up visit were crosstabulated
against baseline symptom severity. Table 20 is an example
of such a crosstabulation. The complete set of these
tables may be found in Appendix 2.
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TABLE 20: SYMPTOM - BURNING SENSATION. 1 WEEK VISIT
FLUCONAZOLE AMPHOTERICIN
Absent Mild Absent Mild Moderate
BASELINE
Absent 19 0 18 1 0
Mild 3 1 1 1 0
Moderate 1 0 0 0 3
Severe 2 0 0 1 0
It is apparent that 19 patients in the fluconazole group
who had no burning sensation at the baseline assessment
continued to have an absence of this symptom after one
week. This symptom was also absent for three fluconazole
patients who had mild baseline severity, for one who had
moderate and for two who had severe symptoms of burning
at the baseline visit. One fluconazole patient who had
mild burning sensations at the baseline assessment
continued to have mild symptoms after one week. Such
comparisons can also be made for the amphotericin group.
For statistical purposes the responses were scored as
absent=0, mild=l, moderate=2 and severe=3. From Table
20 it can be seen that the total number of evaluable
patients in the fluconazole group at one week is 26. It
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is possible to deduce from the figures that the combined
baseline score for these patients, for the symptom
burning sensation, was 12. However at one week the
combined score had fallen to one, a reduction of 11.
The change in score from the baseline to the one week
visit was calculated for each symptom and the results
added together to give the change in total symptom
score. This calculation was repeated for the four week
and the 12 week visits. Table 21 shows the mean change,
from the baseline, in the total symptom score at each
visit, for both treatment groups.
TABLE 21: MEAN CHANGE FROM BASELINE IN TOTAL
SYMPTOM SCORE
1 Week 4 Weeks 12 Weeks
Fluconazole 1.08(n=26) 1.24(n=25) 0.69(n=26)
Amphotericin 0.2 (n=25) 0.57(n=21) 0.52(n=23)
In each case the change is a reduction in score from the
baseline. Although the reduction in total symptom score
was consistently greater in the fluconazole group the
difference between treatments was not significant at any
visit (t test). The greatest reduction in symptom score
was observed at the four week visit.
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The mean changes in total symptom score appear to be of
a rather small magnitude. It should be recalled that the
total number of evaluable patients at each visit, used
for the calculation of the mean, included many patients
who had no symptoms.
Given the way in which the symptoms were graded it would
clearly be possible to recognise when a patients'
symptoms had been cured or improved, in comparison with
the baseline assessment. Table 22 gives the percentage
number of patients at each follow-up visit, whose
symptoms were either cured or improved in comparison with
the baseline assessment.
TABLE 22: SYMPTOMS CURED OR IMPROVED (%)
1 Week 4 Weeks 12 Weeks
F A F A F A
Pain 100 100 75 100 33 50
Burning 86 29 100 43 66 57
Ab. Taste 62 25 62 66 66 33
Dry Mouth 57 36 87 50 85 60
(F=fluconazole, A=amphotericin)
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In each case the percentage figure is based on the total
number of patients at each visit who were symptomatic, or
who had been symptomatic at the baseline assessment. On
the whole the greatest efficacy was observed at the four
week visit when the majority of patients demonstrated
cured or improved symptoms. Pain and burning sensation
were generally more amenable to treatment than abnormal
taste and dry mouth, although the effect on pain appears
not to have been sustained as long as the effect on other
symptoms.
(iii) Concomitant Oral Candidoses
One patient in the fluconazole group had acute
pseudomembranous candidosis at the baseline assessment.
This had resolved by the one week visit but by the 12
week visit it had recurred. One patient in the
amphotericin group had developed acute psuedomembranous
candidosis at the 12 week visit, this condition having
been absent at all previous visits. Two fluconazole
patients had chronic hyperplastic candidosis at the
baseline assessment, both were cured by the four week
visit and remained cured at the long term follow-up.
Table 23 shows the number of patients in each treatment
group with angular cheilitis, at each visit. (Angular
cheilitis was bilateral in every case. )
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TABLE 23: ANGULAR CHEILITIS















The figures in Table 23 represent the same group of
patients progressing through visits, so it is possible to
conclude that of the seven fluconazole patients with
angular cheilitis two were cured by week one, five by
week four, and so on. The numbers are small so
statistical comparisons were not performed. However the
results in each treatment group appear similar. Of those
patients who had angular cheilitis at the baseline almost
three quarters were clear of the condition by one month.
Recurrence of angular cheilitis by 12 weeks appears to
have been more of a problem in the fluconazole group.
Summary: there was no detectable difference between
fluconazole and amphotericin in respect of any measure of
clinical efficacy.
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8. Mycologic Efficacy of Fluconazole and Amphotericin.
If no yeast organisms were cultivated from the swabs or
oral rinse at the follow-up visits, the patient was
deemed to be mycologically cured. In patients not
rendered yeast free it was felt that the most important
indicator of mycologic improvement would be a decrease
in the density of yeast colonisation within the
patients' mouth. This would be reflected in a reduction
in the colony count derived from the oral rinse sample.
Colony counts varied considerably between patients and an
absolute figure representative of improvement could not
be identified. It was decided, therefore, to look at the
figures for each patient in turn and to set an arbitrary
level of 50% reduction in colony count, from the
baseline, as the measure of improvement at each follow-up
visit. Table 24 details the mycologic response to
treatment, showing the number of patients cured, improved
and unchanged at each visit.
More amphotericin than fluconazole patients were
mycologically cured at both the one week and four week
visits. The difference between treatments at four weeks
is statistically significant (p<0.01 chi-square).
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TABLE 24: MYCOLOGIC EFFICACY
1 Week 4 Weeks 12 Weeks
F A F A F A
Cured 8 12 3 10 4 1
Improved 5 5 2 2 0 8
No Change 13 8 20 9 22 14
Total 26 25 25 21 26 23
(F=fluconazole, , A = amphotericin . Cured, improved and :
change are in comparison with the baseline assessment.)
The significantly better cure rates for amphotericin at
four weeks are unsurprising, given that at this stage the
amphotericin group had just completed treatment, whereas
the fluconazole group had completed their treatment 14
days previously. This difference is also reflected in the
combined figures for cure and improvement, expressed in
table 25 in percentage terms.
TABLE 25: MYCOLOGIC CURE OR IMPROVEMENT
1 Week 4 Weeks 12 Weeks
Fluconazole 50% 20% 15%
Amphotericin 68% 57% 39%
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Tables 24 and 25 illustrate the difficulty of
eradicating yeasts from the mouth with antifungal
therapy. The best mycologic response occurred at one week
following which there was a gradual deterioration. This
is well illustrated by Figure 1. No more than half the
patients were cured in either treatment group at any
visit. There is an apparent anomaly in the fluconazole
group (Table 24), in that the number of cured patients
appears to rise from three to four in the period between
the four and 12 week visits. However, it should be
recalled that the number of evaluable cases differed from
visit to visit and there were, therefore, slight
differences in the patient cohorts at each visit.
Summary: the mycologic response was more pronounced and
more prolonged in the amphotericin group. However the
course of amphotericin treatment was twice as long as the
course of fluconazole treatment. Initial reduction in
yeast colonisation in both groups was followed by
repopulation after the cessation of treatment.
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Figure 1. Mycologic cure/improvement, all patients.
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9. Correlation of Clinical and Mycologic Response
Whereas the best mycologic response was observed at one
week the best clinical response was seen at four weeks.
By four weeks the mycologic cure and improvement rate had
begun to decline and this was true even in the
amphotericin group who had only recently completed
treatment. At the 12 week visit there had been
considerable clinical relapse and recurrence and the
decline in mycologic status continued (Figures 2 and 3).
The clinical response appeared to lag behind the
mycologic response.
When the clinical and mycologic status of each patient
were compared at each follow-up visit, there was little
correlation. The hypothesis was that mycologic
improvement, based on a 50% or more reduction in colony
count, derived from the oral rinse, should be reflected
in clinical cure or improvement. No such reduction in
colony count should be reflected in an unchanged clinical
status with respect to the baseline. At the four week
visit correlation between mycologic and clinical response
was observed in only 30% of fluconazole patients and in




















Figure 2. Clinical and mycologic cure/improvement,
fluconazole group.
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Figure 3. Clinical and mycologic cure/improvement,
amphotericin group.
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If clinical response truly lagged behind mycologic
response it might be possible to predict from each
patients mycologic status, what their clinical status
would be at the succeeding follow-up visit. The data for
each patient were examined to see if the mycologic status
at the one week visit could be used to predict the
clinical status at the four week visit and also if the
mycology at four weeks was predictive of the clinical
response at 12 weeks. A mycologic cure or improvement at
week one should then indicate that the patient would be
clinically cured or improved at week four, whereas an
unchanged mycologic status at week one should indicate an
unchanged clinical status at week four, and so on.
Such predictions proved to be correct on only 47% of
occasions for fluconazole patients, and on 56% of
occasions for amphotericin patients. This poor
correlation between clinical and mycologic response
requires explanation. Mycologic cure and improvement
never reached the highest levels of clinical cure and
improvement. Judgement of clinical improvement is, by its
nature, subjective and imprecise. It may also be, that
the criteria adopted to indicate mycologic improvement
were inappropriate. In addition the oral rinse technique
may not be the most suitable for the quantitation of
yeasts in the mouths of denture wearers. The denture
fitting surface is believed to be the most important site
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of yeast colonisation in these patients and even if the
denture is in the mouth when the rinse is performed, the
fitting surface may not be accessible.
It may be that the presence or absence of yeasts grown
from swabs of various oral sites is more relevant to the
clinical response. Yeasts were isolated from the mouths
of 58 (98%) of the 59 patients who entered the study. At
the baseline assessment, yeasts were cultivated from the




Floor of mouth- 73%
Right angle 46%
Left angle 40%
It can be seen that yeasts were isolated most frequently
from the palate, tongue and the fitting surface of the
upper denture. At follow-up visits, at least during the
period of treatment, the frequency of isolation could be
expected to fall, or looked at in the opposite way,
absence of growth at these sites could be a measure of
improvement for the group as a whole. This is illustrated
in Figure 4.
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Figure 4. Percentage of all patients with no yeast
growth derived from palate, denture or tongue.
At the baseline very few patients had no growth derived
from the palate, denture or tongue. The best mycologic
response is observed at one week, when no yeasts were
cultivated from these sites in approximately half of all
patients. The percentage of patients who improved with
respect to yeast growth at these sites is very similar to
that for mycologic cure and improvement based on
reduction in oral rinse colony count. Again the best
mycologic improvement observed does not approach the
level of the best clinical response.
Using yeast growth from the palate or denture fitting
surface as a measure, the correlation between mycologic
and clinical response for the individual patient was
again examined. The hypothesis was that negative culture
from one or both of these sites would represent mycologic
improvement and that this should be reflected in clinical
cure or improvement. Positive culture from both sites
would be reflected in an unchanged clinical status with
respect to the baseline.
When mycologic and clinical results were compared in this
way, for each patient at the four week visit, correlation
was observed in 52% of fluconazole patients and in 73% of
amphotericin patients. If the same measure of mycologic
response was used in an attempt to predict the clinical
response, as previously described for oral rinse colony
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count, predictions were correct on 55% of occasions for
fluconazole patients and on 66% of occasions for
amphotericin patients.
It would appear as though absence of yeast growth from
either the palate or denture, or both, may be a more
relevant indicator of mycologic improvement than 50%
reduction in colony count, as derived from an oral rinse.
The slightly better correlation between clinical and
mycologic response in the amphotericin group may relate
to the length of treatment, the timing of the follow-up
visits and the local application of the drug.
Finally, in this section, it is revealing to look at
mycologic events in those patients who showed an
excellent clinical response and in those whose clinical
response was very poor. An excellent response was defined
as cure which was sustained throughout the study and a
very poor response was defined as an unchanged clinical
status persisting throughout the study. Eight patients
(three fluconazole, five amphotericin) showed an
excellent response. In three of these, yeasts were
completely eliminated at the one and four week visits. In
a further four patients there was a dramatic and
sustained reduction in the number of sites at which
growth occurred and in colony counts. Six patients (four
fluconazole, two amphotericin) showed a very poor
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clinical response. All six patients showed high rates of
yeast recovery throughout the study.
Summary: mycologic improvement based on reduction in
colony count, derived from an oral rinse, did not
correlate closely with clinical events. Positive or
negative yeast culture from the denture, palate, or both,
seemed more pertinent. At the extreme ends of the
spectrum of clinical success the correlation with
mycologic events was clearer.
10. Clinical Outcome in each Classification
of Denture Stomatitis.
The effect of the initial classification of denture
stomatitis on clinical response at each follow-up visit
was examined. Table 26 shows the number of patients with
each classification of denture stomatitis who were either
cured or improved, or unchanged. Patients from both
treatment groups were combined for this analysis. Cure
and improvement for each classification is shown in
percentage terms in Table 27.
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TABLE 26: DENTURE STOMATITIS CLASSIFICATION
Vs CLINICAL RESPONSE
1 Week 4 Weeks 12 Weeks
D H L D H L D H L
Cured/Improved 18 5 7 26 9 10 16 4 4
No Change 13 6 5 4 2 2 13 5 8
Total 31 11 12 30 11 12 29 9 12
(D =Dif fuse, H =Hyperplastic , L=Locali sed )
TABLE 27: CURE/IMPROVEMENT IN DIFFUSE. HYPERPLASTIC
AND LOCALISED DENTURE STOMATITIS
1 Week 4 Weeks 12 Weeks
Diffuse 58% 87% 55%
Hyperplastic 45% 82% 44%
Localised 58% 83% 33%
The clinical response follows the same pattern as
previously observed. Patients appeared to respond equally
well to antifungal treatment, whatever their initial
classification of denture stomatitis had been. Analysis
using the chi-square test showed no significant
association between denture stomatitis classification and
cure or improvement.
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11. Clinical Efficacy. The effect of sex and smoking.
Since the clinical response was similar in both treatment
groups all the patients will be considered together to
study the effect of various patient and prosthetic
factors.
(i) Patient Sex.
Table 28 shows the number of males and females against
clinical response, with respect to the baseline
assessment, at each follow-up visit. Table 29 shows the
percentage of males and females who were clinically cured
or improved at each follow-up visit.
TABLE 28: SEX vs CLINICAL RESPONSE
1 WEEK 4 WEEKS 12 WEEKS
M F M F M F
Cured/Improved 5 23 10 31 5 22
No Change 11 13 2 4 10 13
Total 16 36 12 35 15 35
(M=Male, F=Female)
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TABLE 29: CURE/IMPROVEMENT IN MALES AND FEMALES
1 WEEK 4 WEEKS 12 WEEKS
MALE 31% 83% 33%
FEMALE 64% 89% 63%
Women appeared to respond consistently better than men.
The difference at one week was statistically significant
(p<0.05, chi-square). There was no significant difference
by four weeks and the difference at 12 weeks just failed
to reach significane at the 5% level.
(ii) Smoking status.
Table 30 shows the number
non-smokers, against cli
follow-up visit,in comparison
shows the percentage of
non-smokers who were cured or
visit.
of smokers, ex-smokers and
nical response, at each
with the baseline. Table 31
smokers, ex-smokers and
improved at each follow-up
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TABLE 30: SMOKING STATUS vs CLINICAL RESPONSE
1 WEEK 4 WEEKS 12 WEEKS
S XS NS S XS NS S XS NS
Cured/Improved 8 3 17 16 6 19 12 3 12
No Change 13 4 7 3 1 2 11 4 8
Total 21 7 24 19 7 21 23 7 20
(S=Smoker, XS=Ex-Smoker, NS=Non-Smoker)
TABLE 31: CURE/IMPROVEMENT IN SMOKERS. EX-SMOKERS
AND NON-SMOKERS
1 WEEK 4 WEEKS 12 WEEKS
SMOKERS 38% 84% 5 2%
EX-SMOKERS 43% 8 6% 43%
NON-SMOKERS 71% 90% 60%
Non-smokers seemed to respond better than smokers and
this difference was most marked at one week. The
association between cure or improvement and smoking
status at one week just failed to reach significance at
the 5% level using the chi-square test. However if
ex-smokers are excluded from the analysis the difference
in cure and improvement rates between non-smokers and
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smokers is significant (p<0.05, chi-square). The
difference at four and 12 weeks was not significant. This
implies that the initial response of denture stomatitis
to antifungal treatment is slower in smokers than in
non-smokers.
If this is the case it is interesting to note that whilst
56% of women were non-smokers, only 19% of men were
non-smokers. In fact the association between sex and
smoking status was significant (p<0.05, chi-square). This
may explain, at least partially, why women showed a
better clinical response than men.
12. Denture Wearing Habits
Patients were advised at the begining of the trial to
leave their dentures out at night. Compliance with such
instructions is difficult to estimate. A few weeks after
completion of the trial patients were sent a letter
containing two questions as follows:
1. Before you began the treatment did you leave your
dentures in at night? YES/NO
2. Do you now leave your dentures in at night? YES/NO
A stamped addressed envelope was provided for reply.
- 144 -
It was felt that if these questions were asked after
completion of the trial patients would be more inclined
to answer honestly. Forty six of the 59 patients replied,
22 of whom had received fluconazole and 24 of whom had
received amphotericin. Of these 46 patients, 27 said that
before the trial began they had worn their dentures at
night (13 fluconazole, 14 amphotericin). Fourteen said
that they now wore their dentures at night (8
fluconazole, 6 amphotericin). Therefore, if the responses
are to be believed, 13 of 27 patients who had originally
worn their dentures at night had followed instructions
and were now leaving their dentures out at night.
Patients who wear their dentures at night can be
considered as more or less constant denture wearers, as
opposed to day-time only wearers. The effect of constant
denture wearing on cure and improvement rates was
examined. It was assumed that the patients' responses to
the questionaire were truthful and their response to the
second question was taken to indicate whether they were
constant or day-time only denture wearers at the time of
the trial. Table 32 shows the number of constant and
day-time denture wearers who were cured or improved, or
unchanged, at each visit.
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TABLE 32: DENTURE WEARING vs CLINICAL RESPONSE
1 WEEK 4 WEEKS 12 WEEKS
C D C D C D
Cured/Improved 10 14 9 25 7 15
No Change 4 15 2 3 5 16
Total 14 29 11 28 12 31
(C=Constant denture wearers, D =Day-time denture wearers)
At one week, 71% of constant denture wearers were cured
or improved compared with 48% of day-time only wearers.
This discrepancy is surprising but it did not continue
throughout the study. At four weeks 82% of constant
denture wearers were cured or improved compared with 89%
of day-time only wearers and at 12 weeks the figures are
58% and 48% respectively. The apparently better early
response in constant denture wearers was not
statistically significant but is nonetheless intriguing.
It might be that it is related to topical application of
the drug in amphotericin patients. If the results at one
week are broken down into treatment groups, 75% of
constant denture wearers taking fluconazole were cured or
improved compared with 66% of constant denture wearers
taking amphotericin. The trend is therefore opposite to
what might be expected if topical drug application
combined with constant denture wearing had some benefit.
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13. Clinical Efficacy.
The effect of prosthetic factors.
The effect of various prosthetic factors on the clinical
response to treatment was evaluated. In these evaluations
all patients were considered together, including those
who had attended outside the defined follow-up visit
windows. It should be recalled that certain of the
denture quality assessments were not considered
applicable to some patients.
(i) Upper Denture Type
Table 33 shows the number of patients wearing complete
upper and partial upper dentures against clinical
response at each visit. Percentage figures for
cured/improved are given in parentheses.




No Change 11 13
Total 30 24
(C=Complete denture, P=Partia
4 WEEKS 12 WEEKS
C P C P
28(93) 17(74) 15(53) 12(54)
2 6 13 10
30 23 28 22
denture)
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Although the figures suggest that complete denture
wearers showed a better clinical response than partial
denture wearers, the difference was not significant at
any visit. One possible explanation for any difference
observed might be that the gingival crevice provides an
additional reservoir of yeast organisms in partially
dentate individuals. If this were so, might fluconazole,
secreted in gingival crevicular fluid, prove a more
effective drug for the treatment of denture stomatitis in
patients with partial dentures? Table 34 shows the number
of patients wearing upper partial dentures, in each
treatment group, against clinical response at each visit.
Percentage figures for cured/improved are given in
parentheses. For both Tables 33 and 34 the categories
cured and improved are in comparison with the baseline.
TABLE 34: CLINICAL RESPONSE IN UPPER PARTIAL DENTURE




No Change 8 5
Total 14 10
(F=Fluconazole, A=Amphoteri
4 WEEKS 12 WEEKS
FA FA
9(64) 8(89) 7(50) 5(62.5)
5 1 7 3
14 9 14 8
in)
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Although the numbers involved are small, the hypothesis
that fluconazole is a better drug for the treatment of
denture stomatitis in the partially dentate is not
supported.
(ii) Denture Quality
The effect of each of the denture quality
factors, assessed at the baseline visit, on clinical
outcome was studied. The results are summarised in Tables
35-40. These tables show the percentage number of
patients who were cured or improved against the denture
quality factor assessment (in Table 35, of those patients
who had good denture retention, 64% were cured or
improved at one week, 100% at four weeks and 33% at 12
weeks, and so on). Cure/improvement is in comparison
with the baseline.
TABLE 35: CURE/IMPROVEMENT vs DENTURE RETENTION
1 Week 4 Weeks 12 Weeks
Good 64% 100% 3 3%
Fair 50% 80% 80%
Poor 59% 82% 53%
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TABLE 36: CURE/IMPROVEMENT vs DENTURE STABILITY
1 Week 4 Weeks 12 Weeks
Good 56% 94% 47%
Fair 54% 83% 58%
Poor 61% 83% 60%
TABLE 37: CURE/IMPROVEMENT vs DENTURE EXTENSION
1 Week 4 Weeks 12 Weeks
Good 61% 95% 42%
Fair 47% 82% 62%
Poor 62% 80% 61%
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TABLE 38: CURE/IMPROVEMENT vs DENTURE HYGIENE
1 Week 4 Weeks 12 Weeks
Good 53% 87% 47%
Fair 59% 89% 60%
Poor 60% 78% 55%
TABLE 39: CURE/IMPROVEMENT vs OCCLUSION
1 Week 4 Weeks 12 Weeks
Good 43% 75% 21%
Fair 61% 83% 58%
Poor 68% 91% 70%
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TABLE 40: CURE/IMPROVEMENT vs VERTICAL DIMENSION
1 Week 4 Weeks 12 Weeks
Dec reased 73% 91% 70%
Correct 60% 76% 47%
Increased 50% 100% 50%
For the most part the individual denture quality factors
appear to have had no detectable influence on the
clinical response to treatment. In other words, for each
factor assessed, patients with good, fair or poor
dentures responded equally well to antifungal treatment.
This was not true for denture retention and occlusion at
the 12 week visit. At this visit there was a significant
association (p<0.05, chi-square) between denture
retention and cure/improvement, patients with fair
retention apparently responding better than those with
good or poor retention. Also at the 12 week visit, there
was a significant association (p<0.05, chi-square)
between occlusion and cure/improvement. Patients with
poor occlusion responded better than those with fair, who
in turn responded better than those with good occlusion.
(The chi-square test was used where the differences
appeared marked, using the actual proportions and not the
percentages displayed in the tables.)
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Patients with decreased occlusal vertical dimension
seemed to show a better response to treatment than those
with correct occlusal vertical dimension. However the
differences were not significant at any visit. It is
useful to recall, when looking at table 40, that there
were only two patients in the whole group who had
increased vertical dimension.
14. Haematology and Liver Function Tests.
At the baseline assessment, only seven of 59 patients
displayed a haematologic deficiency. Five patients (four
assigned to fluconazole and one to amphotericin) had a
low serum ferritin and two patients (both assigned to
receive amphotericin) had a low serum folate. One of the
patients with low serum folate was excluded from analysis
due to poor compliance with treatment. All of the six
remaining patients responded to treatment despite the
fact that the deficiencies were not corrected.
During the period of active treatment no adverse changes




Yeasts from all sites sampled were speciated. Yeasts were
most frequently isolated from the palate, denture and
tongue. Qualitative changes in the yeast flora at these
three sites during the period of the study are considered
in this section.
Three sites in 59 patients gives a total of 177 sites.
The relative frequency of different yeast species at
these sites, at the baseline visit, was as follows:
No growth - 10.2%
Candida albicans - 69.5%
Candida glabrata - 16.4%
Saccharomyces cerevisiae - 5.1%
Unidentified - 2.2%
The percentages do not add up to 100 since there was
mixed growth (growth of more than one organism) at 3.4%
of sites. This level of mixed growth remained much the
same throughout the study. At the baseline visit, mixed
growth was always a combination of C. albicans and
C. glabrata. At follow-up visits, other combinations
were observed.
Changes in the relative frequency of yeast species
isolation during the course of the study are shown, for
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the fluconazole group in Table 41 and for the
amphotericin group in Table 42. The percentages are based
on the total number of sites (palate, denture and tongue)
sampled for each group at each visit.
TABLE 41: YEAST SPECIES. FLUCONAZOLE GROUP.
Baseline 1 Week 4 Weeks 12 Weeks
No Growth 9% 36% 2 5% 21%
C.albicans 71% 39% 5 5% 5 5%
C.glabrata 19% 20% 21% 16%
S.cerevisiae 7% 6% 1% 4%
C. parapsilosis - 3 . 6% - -
Unidentified - - 10% 4%
TABLE 42: YEAST SPECIES. AMPHOTERICIN GROUP
Baseline 1 Week 4 Weeks 12 Weeks
No Growth 11% 61% 52% 24%
C.albicans 68% 27% 38% 64%
C.glabrata 13% 6% 6% 10%
S.cerevisiae 3% - - 4%
C.tropicalis - - 5% -
Rhodotorula spp. 1%
Unidentified 4% 9% 1% 4%
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At the baseline visit there was little difference between
the two treatment groups in terms of the relative
frequency of yeast species isolated. The changes also
follow a similar pattern in both groups, with no growth
being maximal at one week followed by a progressive
recolonisation of sites. However amphotericin seemed to
be more effective in eliminating yeast growth than
fluconazole and this has already been demonstrated in
this chapter (see section 8). The increased number of
sites at which no growth occurred at follow-up visits,
compared with the baseline, seemed to be largely at the
expense of Candida albicans. The changes in the
frequency of this organism seemed to be almost the
opposite of the changes in "no growth".
In the fluconazole group the frequency of isolation of
Candida glabrata remained almost unchanged throughout
the study. At the baseline visit a total of 11 patients
had C. glabrata isolated from one or more of the
palate, denture or tongue. Of these 11, six were assigned
to receive fluconazole and five to receive amphotericin.
Of the six fluconazole patients C. glabrata persisted
throughout the study in three cases and in two cases it
was only eliminated at the final visit. C. glabrata
was completely eliminated throughout the study in three
of the five amphotericin patients. The sustained
frequency of isolation of C. glabrata in the
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fluconazole group can therefore be largely explained by
the persistent isolation of the organism from the same
patients. C. glabrata occurred in only one fluconazole
patient at follow-up visits in whom it had not occurred
at the baseline.
Of the 11 patients in whom C. glabrata had been
isolated at the baseline, none failed to attend at any
follow-up visit. These patients therefore had a total of
33 follow-up visits. C. glabrata was isolated at 18
of these patient visits and on 14 of these visits at all
three sites (palate, denture and tongue). Persistance of
C. glabrata was associated on two occasions with a
clinical cure, on six occasions with a clinical
improvement and on 10 occasions with an unchanged
clinical status in relation to the baseline. Complete
elimination of C. glabrata was associated on two
occasions with clinical cure, on seven occasions with
clinical improvement and on six occasions with an
unchanged clinical status in relation to the baseline.
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Six of the 11 patients in whom C. glabrata had been
isolated at the baseline, were men. This is a far higher
proportion of men than in the experimental group as a
whole. Seven of the 11 were smokers and four were
non-smokers, although this appears to have had little
effect on the mycologic or clinical response in this
sub-group of patients.
Other yeast species occurred with varying frequency and
in no particular pattern. They usually replaced
eliminated C. albicans and were almost always
associated with improved clinical status.
Summary: Fluconazole and amphotericin were both
effective in reducing the frequency of isolation of
Candida albicans, although amphotericn was more so.
Candida glabrata seemed relatively resistant to
fluconazole.
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16. Humoral Immune Response.
The data for almost all of the estimations of
immunoglobulin concentration were markedly asymmetrical.
The median is therefore a better measure of the
centrality of the distribution of the data than the mean.
The median values for total, isotype specific, salivary
and serum immunoglobulin concentrations are given in
Tables 43 and 44.
TABLE 43: MEDIAN VALUES OF TOTAL SALIVARY
IMMUNOGLOBULIN LEVELS (IU/litre)
Baseline 1 Week 4 Weeks 12 Weeks
F A F A F A F A
IgG o o CO 0 .31 0 . 0 0 .19 0 . 0 0 . 0 o to 00 0 . 32
IgA 5 . 6 5 . 2 4 . 85 4 . 9 5 . 1 4 . 72 5 . 5 5 . 27
IgM oo oo oo oo oo oo o o oo
(F=fluconazole, A=amphotericin)
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TABLE 44: MEDIAN VALUES OF TOTAL SERUM
IMMUNOGLOBULIN LEVELS (lU/ml)
Baseline 1 Week 4 Weeks 12 Weeks
F A F A F A F A
IgG 211 243 203 227 203 211 195 227
IgA 26 34 26 32 25 31 27 28
IgM 37 24 36 33 34 30 37 32
(F=fluconazole, A=amphotericin]
The median values for salivary and serum anti-candidal
antibody concentrations are given in Tables 45 and 46.
TABLE 45: MEDIAN VALUES OF SALIVARY ANTI-CANDIDAL
IMMUNOGLOBULIN LEVELS (ELISA units)
Baseline 1 Week 4 Weeks 12 Weeks
FA FA FA FA
IgG 4.91 3.56 2.4 2.77 2.4 4.0 2.66 3.32
IgA 62.36 44.57 58.31 44.64 49.94 58.44 61.9 49.07
IgM 9.74 9.00 10.69 8.99 11.33 7.95 7.5 8.52
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TABLE 46: MEDIAN VALUES OF SERUM ANTI-CANDIDAL
IMMUNOGLOBULIN LEVELS (ELISA units)
Baseline 1 Week 4 Weeks 12 Weeks
F A F A F A F A
IgG 149 304 240 362 184 264 136 276
IgA 48 20 47 15 36 56 29 66
IgM 301 54 192 123 100 103 100 102
The range of concentrations observed for a given
immunoglobulin at a particular visit was often
considerable. For this reason relatively small changes in
median immunoglobulin concentrations over the course of
the study should be interpreted with caution. With this
in mind it is possible to make the following
observations.
Immunoglobulin concentrations were generally higher in
serum than in saliva, with the exception of anti-candidal
IgA, which was higher in saliva. In serum, IgG was the
predominant isotype. There were similar levels of total
serum IgA and IgM. In saliva, IgA was by far the
predominant isotype. Total salivary IgG was present in
slightly higher levels than total salivary IgM.
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Total salivary immunoglobulin levels tended to fall
slightly in response to treatment and then rise after the
completion of treatment. Total serum immunoglobulin
levels tended to remain unchanged throughout the study.
Salivary anti-candidal IgG fell in the fluconazole group
after the baseline visit and then remained at a fairly
constant level whereas in the amphotericin group it had
fallen by one week and then rose again subsequently. A
similar falling then rising pattern was observed for
salivary anti-candidal IgA in the fluconazole group.
However in the amphotericin group,salivary anti-candidal
IgA remained quite constant. Salivary anti-candidal IgM
levels also tended to remain constant.
By week one serum anti-candidal IgG had risen from
baseline levels for both treatment groups but by four
weeks it had fallen, the concentration in the
amphotericin group being less than at the baseline. In
the fluconazole group, serum anti-candidal IgA and IgM
both fell after the baseline visit and failed to rise
after the completion of treatment. In the amphotericin
group serum anti-candidal IgA had fallen by one week but
then rose to levels higher than at the baseline.
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The most frequently observed pattern of change then, was
a fall in immunoglobulin levels at some stage during the
treatment period. This was sometimes followed by a rise
in immunoglobulin levels after treatment had ceased. This
seemed to be more apparent in salivary than in serum
immunoglobulins. It must be re-emphasised that the
changes in the median values were small and the range of
values, in most cases, wide.
Differences were observed in the humoral immune response
of smokers and non-smokers. Immunoglobulin levels,
particularly in serum, were frequently higher in
non-smokers than in smokers. The following total and
anti-candidal immunoglobulins were present in
significantly higher concentrations in non-smokers than
smokers:
Baseline - Total serum IgG, p<0.01
Serum anti-candidal IgG, p<0.01
1 Week - Total serum IgG, p<0.05
Total serum IgA, p<0.05
Serum anti-candidal IgG, p<0.01
4 Weeks - Total serum IgA, p<0.05
Serum anti-candidal IgG, p<0.01
12 Weeks - Total serum IgA, p<0.05
Serum anti-candidal IgG, p<0.001
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The Mann-Whitney and Wilcoxon rank sum non-parametric
tests of significance were used. As can be seen,
significant differences between smokers and non-smokers
were observed in serum but not in salivary immunoglobulin
levels.
Summary: immunoglobulin concentrations in serum and
saliva varied widely between patients and showed
relatively small changes in response to antifungal
treatment. The humoral immune response in smokers seemed
to be depressed in comparison with non-smokers.
17. Adverse Reactions to Treatment.
Adverse reactions to treatment were rare. Only three of
the 29 fluconazole patients and five of the 30
amphotericin patients experienced adverse events related
or possibly related to treatment. One fluconazole and two
amphotericin patients reported the adverse reaction as
severe. The single fluconazole patient developed
pharyngitis which was tolerated. Of the two amphotericin
patients with severe adverse reactions, one developed a
burning mouth and the other complained of nausea. This
last patient permanently discontinued treatment as a




A PRELIMINARY STUDY OF THE CELLULAR
IMMUNE RESPONSE IN DENTURE STOMATITIS
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1 . Introduction
The cellular immune response is thought to be of primary
importance in combating systemic fungal infections177.
The same would appear to be true of denture stomatitis,
indeed the inflammation seen has been ascribed to a
delayed-type hypersensitivity response82'96'97. In
contrast it has been suggested that denture stomatitis is
associated with suppression of the cellular immune
response178-179. Most studies have used the inhibition
of leucocyte migration as a measure of the cellular
immune response in patients with denture stomatitis. In
one study the phagocytosis of yeasts by leucocytes from
patients with denture stomatitis was found to be
normal180. In another study, no difference was found in
the lymphocyte transformation response of patients with
denture stomatitis and controls181 although the
controls do not appear to have been screened for candidal
carriage and only one mitogen, phytohaemagglutinin
(PHA), was used. If the cellular immune response is
depressed in patients with denture stomatitis the
possibility exists that this may be innate or induced by
Candida. To try and clarify this, lymphocyte
transformation tests were performed using patients with
denture stomatitis, other oral candidosis and healthy
controls who were either carriers or non-carriers of






in the same patient
lymphocyte transformation
before and after antifungal
2. Materials and Methods
Approximately 30 mis of heparinised venous blood were
obtained from patients with denture stomatitis, patients
with candidal leukoplakia and controls who had been
determined positive or negative for candidal carriage.
Blood was obtained from two denture stomatitis patients
and two leukoplakia patients both before and after
antifungal treatment.
Twenty five ml of whole blood, previously diluted 1:2
with RMPI 1640 medium was layered onto 20 ml of a
premixed commercial preparation of Ficoll-Hypaque
(Lymphoprep, Flow Laboratories, Rickmansworth, UK) in 50
ml polystyrene disposable tubes. The tubes were then
centrifuged at 20 °C for 25 minutes at 400xg.
Mononuclear lymphocytes and monocytes were recovered at
the Ficoll-Hypaque-plasma interface and washed twice in
RMPI 1640. The leucocyte suspensions were then diluted
with dimethyl sulphoxide (Sigma, Poole, Dorset, UK) and
placed in a cryopreserving freezer and stored at -70 °C.
Prior to performing the lymphocyte transformation assay
the leucocyte suspensions from the appropriate subjects
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were defrosted, washed three times with phosphate
buffered saline and cell viability checked using the
trypan blue dye exclusion test. The leucocytes were
counted in an automatic cell counter and adjusted to an
appropriate working concentration.
The leucocytes were cultured in round bottomed microtitre
culture plates (Flow Laboratories, Rickmansworth, UK).
The cultures, in triplicates, contained 2xl05
leucocytes in a final volume of 0.2 mis consisting of
RMPI 1640 supplemented with 10% foetal calf serum, 100
units/ml of penicillin and 100 ug/ml of streptomycin.
Leucocyte proliferation was induced by PHA at a
concentration of 1.2ug/ml, pokeweed mitogen at a
concentration of lug/ml and heat-killed C. albicans at
a concentration of lxlO6 organisms/ml. The cultures
were incubated for three days for mitogens and five days
for antigen at 37 °C in a humidified atmosphere of 5%
carbon dioxide in air. 3H-thymidine (Amersham
International PLC, Amersham, UK) in a dose of 0.5 uCi per
well, was added for the last four hours of incubation. A
set of triplicate cultures containing no mitogen or
antigen served as the control for background thymidine
incorporation.
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The cultures were harvested using a semi-automated cell
harvester (Titertek, Flow Laboratories, Rickmansworth,
UK) onto glass-fibre filter paper. The fibre-glass
filters, containing the harvested cells, were immersed in
vials containing 3 mis of scintillation fluid (Fisons
Scientific Apparatus, Loughborough, UK) and the
radioactivity counted in a liquid scintillation counter
(Pakard Tri-Carb Ltd., Caversham, UK). The amount of
3H-thymidine incorporated by the cells was expressed as
the mean counts per minute (cpm).
The materials and methods described are essentially the
same as those described by Wray235 , except for the
freezing of the leucocytes. Six separate assays were
performed, each containing leukocytes from one control
positive for candidal carriage, one control negative for
candidal carriage, one denture stomatitis patient and one
candidal leukoplakia patient. For two of the six assays
leukocytes were tested which had been obtained from the
denture stomatitis patient prior to and after antifungal
therapy. Also in two assays, leucocytes were tested from




Tables 47 to 52 give the results of the six assays,
expressed in mean counts per minute for each set of
leucocyte cultures. The stimulation index is given in
parentheses beneath the relevant cpm figure. The
stimulation index is calculated by dividing the mean cpm
of the stimulated cells by the mean cpm of the
unstimulated control cells. An explanation of the
abbreviations used can be found at the end of the results
section.
TABLE 47: LYMPHOCYTE TRANSFORMATION ASSAY 1.
PATIENT PHA PWM C. ALB CELLS
Controls- 87,912 67,440 3547 42
(2093 ) (1606 ) ( 84 )
Control- 16,557 71 ,450 22,780 129
(128) ( 554 ) (176)
DS 24,273 68 ,450 4759 40
( 60 7 ) ( 1711 ) (119)
Leuk 71 70 95 35
(2 ) (2) (2.7)
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TABLE 48: LYMPHOCYTE TRANSFORMATION ASSAY 2.
PATIENT PHA PWM C. ALB CELLS
Control+ 41 ,422 97 , 797 103 42
( 986 ) ( 2328 ) (2.4)
Control- 136,425 58,570 10 ,831 171
( 798 ) ( 342 ) ( 63 )
DS 189,057 82,919 25,407 66
(2864 ) (1256 ) ( 385 )
Leuk 42,260 2820 66
( 640 ) (43)
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TABLE 50: LYMPHOCYTE TRANSFORMATION ASSAY 4.
PATIENT PHA PWM C.ALB CELLS
Control* 65,085 68,016 15,591 63
(1033 ) ( 1080 ) ( 247 )
Control- 32,112 52,827 14 , 143 105
( 306 ) ( 503 ) (135)
DS pre 20,791 68,528 1972 28
( 742 ) (2447) (70)
DS post 31 , 395 68,880 11,091 39
( 805 ) ( 2535 ) ( 284 )
Leuk 86,412 56,619 20,404 1457
(59) (39) (14)
TABLE 51: LYMPHOCYTE TRANSFORMATION ASSAY 5.
PATIENT PHA PWM C. ALB CELLS
Control+ 48 , 904 87,050 2495 97
( 504 ) ( 897 ) ( 26 )
Control- 78,008 71 ,840 12,807 50
(1560 ) (1437) ( 256 )
DS 30,669 83,580 1964 166
(185) ( 503 ) ( 12 )
Leuk pre 42,118 48 ,275 8762 104
( 405 ) ( 464 ) (84)
Leuk post 53,321 59,697 25,291 99
( 538 ) ( 603 ) ( 255 )
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TABLE 52; LYMPHOCYTE TRANSFORMATION ASSAY 6.
PATIENT PHA PWM C.ALB CELLS
Control+ 110,031 86,859 14,828 487
( 226 ) (178 ) (30 )
Control- 161,321 84,595 12,521 62
(2601 ) (1364 ) ( 202 )
DS 123 , 958 442 20,824 42
(2951 ) ( 10 ) ( 496 )
Leuk pre 96,200 72 ,436 912 62
(2237 ) (1684 ) (21 )
Leuk post 79,714 76,301 3978 35





CELLS, Unstimulated control cells
Control+, Control patient positive for candidal carriage
Control-, Control patient negative for candidal carriage
DS, Denture stomatitis patient
Leuk, Candidal leukoplakia patient
pre, before antifungal treatment
post, after antifungal treatment
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4. Summary of Results and Discussion
There was no consistent relationship between the
lymphocyte response of control patients who were or were
not carriers of Candida. However in four of the six
assays the stimulation index of carrier leucocytes
challenged with C. albicans was less than that of
non-carrier leucocytes. If Candida were responsible for
causing depression of cellular immune response a graded
lymphocyte response to C. albicans might be
anticipated, with the highest stimulation index in
non-carriers, the next highest in healthy carriers and
the lowest in patients with clinical candidal infection.
Such a gradation could not be consistently demonstrated.
In four of the six assays leucocytes from patients with
candidal leukoplakia showed a lower stimulation index
than those from patients with denture stomatitis when
challenged with C. albicans. The same relationship was
generally true for mitogen stimulation also.
The most interesting feature of the results relates to
the effect of antifungal treatment. Antifungal treatment
of both denture stomatitis and candidal leukoplakia
always led to an increased stimulation index in
leucocytes callenged with C. albicans, compared with
that seen in leucocytes from the same patients before
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treatment. The response of leucocytes to stimulation with
mitogens remained unchanged by antifungal treatment. This
would seem to suggest that Candidal infection can cause
depression of the cellular immune response but that this
may be confined to the ability to respond to Candida,
antigens. The cellular immune response to Candida
antigen would seem to be restored following antifungal
therapy. Expansion of this preliminary study was not
possible owing to the limitations of time and funding.
The small numbers involved make statistical analysis
inappropriate. The trends seen, however, are interesting





The use of antifungal drugs is an acceptable option for
the treatment of denture stomatitis62. The rationale
for such treatment is based on compelling evidence
indicating that yeasts are the prime cause of the disease
(see Chapter 1). Indeed the improvement seen during use
of antifungals is often cited as proof of the causitive
role of yeasts in denture stomatitis. However antifungal
drugs are frequently only partially successful in
alleviating the signs and symptoms of the
disease15 '69< 182 - 185 • 186 . Furthermore, once treatment
is stopped , relapse and recurrence are very
common12'29-32'69'183. Explanations for the often
disappointing outcome of antifungal therapy have included
re-infection from exogenous as well as endogenous
sources15'17'182, in addition to the involvement of
other factors in the aetiology of the condition18'185.
Despite the fact that the aetiology of denture stomatitis
is said to be multifactorial61'62 the influence of
these other factors on the efficacy of antifungal therapy
has rarely, if ever, been properly investigated. The
broad aim of the work reported in this thesis was to
conduct just such an investigation.
Inquiry into the effect of a number of factors on the
outcome of antifungal therapy might help to shed light on
the inter-relationship of these factors in the aetiology
of denture stomatitis. In this respect the term
"multifactorial" requires some consideration. It could be
taken to mean two things: firstly that a number of
factors could act totally independently to produce
conditions with very similar signs and symptoms, and
secondly, that a number of factors may act together to
produce the signs and symptoms of the condition. In the
first case there would be a number of conditions which,
whilst clinically indistinguishable, would have quite
separate causes, and in the second case one condition
might have a varying number of factors contributing to
the aetiology. The literature is not helpful in
deciding which of these definitions is most appropriate
in describing the aetiology of denture stomatitis.
A previously published trial had indicated that
fluconazole was an effective treatment of denture
stomatitis when compared with a placebo13. The next
logical step was therefore a comparative trial of this
new drug with a drug such as amphotericin, which,
although useful, had demonstrated some of the
shortcomings in efficacy described above. Not only would
two different types of antifungal agent be compared but
two different modes of administration, which, if theories
about re-infection from endogenous sites and patient
compliance were correct, might significantly effect the
outcome of treatment.
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Fifty nine patients were entered into a comparative trial
of the two antifungal agents. The patients were randomly
assigned to recieve either fluconazole or amphotericin,
the first of these being a systemically administered and
the second a topically administered antifungal drug. A
number of variables which might possibly have influenced
the outcome of treatment were recorded and where possible
quantified. These variables included the initial severity
of denture stomatitis, the patients' sex and smoking
status, denture wearing habits, the type and quality of
the patients' denture, haematologic abnormalities, the
yeast species involved and the patients compliance with
treatment. In terms of these variables the randomisation
process produced quite evenly matched treatment groups.
There were some slight differences: on average, patients
in the amphotericin group were slightly older (60 years)
than those in the fluconazole group (50 years), the
fluconazole group had a slightly higher percentage of
smokers than did the amphotericin group and whilst the
amphotericin group had slighlty more complete upper than
partial upper denture wearers, complete and partial upper
dentures were equally distributed in the fluconazole
group. For all the other variables, observed differences
between treatment groups, where they occurred, were only
minor.
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Fifty nine patients might be thought a small number. As
far as the known variables are concerned 59 proved to be
a sufficient number to allow the randomisation process to
work effectively. It seems reasonable to assume
therefore, that unknown variables were also evenly
distributed between the treatment groups. The size of an
experimental group also determines the ability of a study
to detect real differences where they occur. Clearly the
larger the sample the better. The comparisons reported in
this thesis did demonstrate statistically significant
differences in some cases. In fact 59 is a greater number
of patients than have been involved in most
previously reported studies of antifungal treatment
of denture stomatitis10,i2,i3,i82,i85,i88-i90,2i2) au
of which have involved fewer investigations than the
present study.
Before considering the clinical and mycologic efficacy of
the drugs some of the presenting features of the patients
will be discussed. There were almost two and a half times
as many women as men. The vast majority of these patients
were otherwise in good health and the incidence of
haematologic deficiency was small (five patients had a
low serum ferritin and two had a low serum folate). Just
over half the patients wore a complete upper denture, the
remainder wearing a partial upper denture. Only one third
of these dentures were judged to be of a good overall
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quality. In particular, denture retention, stability and
occlusion were often poor. The commonest type of denture
stomatitis was diffuse erythematous, accounting for
slightly more than one half of the patients. The
remaining patients had localised erythematous or
hyperplastic/granular forms of the condition in
approximately equal numbers. Symptoms were reported by
52.5% of patients, the most frequent complaint being of
dry mouth. Symptoms occurred most commonly in those with
the hyperplastic/granular from of denture stomatitis. The
commonest concomitant oral candidosis was angular
cheilits which occurred in 18.6% of patients and which
was bilateral in each case.
The proportion of patients with the diffuse form of
denture stomatitis was higher than in previous
studies46•50>51 •5 4 - 5 5 • 59 whilst fewer patients had
angular cheilits than might have been
expected8- 15• 18 • 25 • 27>33 " 35 . The proportion of patients
with symptoms was similar to that previously
reported27-29. However the majority of symptoms were
mild and general awareness of the condition was low.
Comparison of these presenting features with those
reported in previous studies may be misleading. In this
study the patient sample was highly selected. Potential
patients were frequently excluded from entry into the
study based on the criteria described in chapter two.
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The small number of haematologic deficiencies were not
corrected and this did not appear to influence the
outcome of treatment in these patients. This lends
support to previous studies which have been unable to
demonstrate a relationship between iron and folate
deficiencies and denture stomatitis150'151.
Maximum clinical efficacy was observed for both drugs at
the four week visit, when 84% of fluconazole and 91% of
amphotericin patients were cured or improved. At this
stage it is likely that the number of cured and improved
patients in the fluconazole group was already declining
since they had completed treatment two weeks previously,
in accordance with the protocol. The design of the trial,
therefore, probably did not allow the maximum clinical
efficacy of fluconazole to be detected. However this
would appear to be unimportant given the high rate of
relapse and recurrence observed by the 12 week follow-up
visit.
The difference between treatments, in terms of clinical
response, was not significant at any visit. Fluconazole
treatment was completed after two weeks and amphotericin
treatment after four, and yet at the four week visit
there was no significant difference between the two
treatment groups. This may indicate that the improvement
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produced by fluconazole was more prolonged. The trend
seen at the 12 week visit, when 58% of fluconazole
patients were cured or improved compared with 50% of
amphotericin patients, may support this assumption. If
this were the case then a possible explanation could be
the systemic effect of fluconazole, which might reduce
the chances of re-inoculation of yeasts from endogenous
sites such as the vagina or the gut. However this study
does not provide convincing evidence to support this
theory.
Budtz-Jorgensen et al13 reported 16% of patients with
denture stomatitis were cured and 73% improved after two
weeks of fluconazole treatment. The total of 89% cured or
improved by fluconazole compares well with the 84% cured
or improved seen in the present study two weeks after the
completion of treatment. However, in the present study
44% of patients were cured. A similar means of patient
selection was used in both studies and although different
means of assessing improvment in palatal erythema were
used, "cure" would seem to be unequivocal. In the study
by Budtz-Jorgensen et al13 patients were given no
instructions regarding denture hygiene, whereas in the
present study they were. Although compliance with such
instructions is difficult to estimate this does seem to
be a likely explanation for the difference in cure rates
between the two studies. Furthermore in the
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Budtz-Jorgensen et al study13 relapse had occurred
in virtually all patients by four weeks after the
completion of treatment. In the present study, although
there was considerable relapse and recurrence, at the
twelve week visit, at least half the patients in both
treatment groups were still cured or improved. Good
denture hygiene may have contributed to the sustained
improvement seen in these patients. It therefore seems
reasonable to suggest that a combination of denture
hygiene measures and antifungal treatment results in a
more pronounced and prolonged improvement in denture
stomatitis than antifungal treatment alone.
It is interesting to note that patients with each
classification of denture stomatitis responded equally
well to antifungal treatment. This contradicts the view
that the localised form of the condition is caused by
denture trauma and suggests instead, that it is a mild
form of Candida.-associated denture stomatitis.
The symptoms of pain, burning sensations, dry mouth and
abnormal taste were cured or improved by antifungal
treatment in the majority of patients and there were no
significant differences between fluconazole and
amphotericin. It is not possible to say with certainty
why antifungal treatment failed to improve some patients'
symptoms. This may have been due to poor drug efficacy
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but it may also have been that the symptoms had other
causes. Where symptoms were improved it seems likely
that they were associated with denture stomatitis.
However a placebo effect cannot be discounted. It is
interesting that over half the patients who complained of
dry mouth reported this symptom to be resolved or reduced
following antifungal treatment. It seems likely that a
feeling of dryness of the mouth may, in some cases, be
caused by oral candidosis and this may have contributed
to the belief that xerostomia predisposes to such
infections.
Antifungal treatment also resulted in the improvement of
a number of concomitant oral conditions. In the case of
angular cheilitis this may appear to implicate yeasts in
the aetiology. However improved denture plaque control
may also have reduced the bacterial population in the
mouth. Previous studies have indicated that the infective
aetiology of angular cheilitis is complex and that in
many cases bacterial infection is more significant than
candidal infection38 >39 .
Fuller explanation of the clinical response requires
consideration of the mvcologic events. Mycologic cure was
taken to be complete eradication of yeasts from the
mouth (i.e. when no yeasts were cultivated from any of
the six sites sampled by swabbing or from the oral
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rinse). In patients not rendered yeast free a decrease
in the density of yeast growth was taken to indicate
improvement. This approach has been adopted in other
studies10'13'64*69'182'185'186'190. However the methods
used in many of these studies could only be described as
semi-quantitative. Methods for quantitative assessment of
yeast colonisation of oral surfaces have been
compared228 and the imprint culture and concentrated
rinse culture methods found to be equally sensitive. The
concentrated rinse method was found to be superior for
quantifying very high densities of organisms. An oral
rinse culture was used in the present study but two
problems were encountered. Firstly, there are no data
available to suggest whether denture wearers should have
their dentures in or out of the mouth during rinsing. If
the dentures are out of the mouth then the denture
fitting surface, which is a prime site of yeast growth,
will not be sampled. However if the dentures are worn
during rinsing it is still possible that the denture
fitting surface will not be sampled and in addition the
covered area of the palate may not be sampled. Most
patients in the present study rinsed with their dentures
out but some found it difficult to expectorate unless the
dentures were worn. These patients wore their dentures
when rinsing. Hence comparisons of yeast density between
patients cannot be made. However patients either wore or
did not wear their dentures consistently throughout the
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study and it is therefore possible to make comparisons
between visits for individual patients.
A very wide range of colony counts was obtained and it
was not possible to identify figures representative of
infection or improvement. Indeed it may be quite
impossible to identify such figures since it seems likely
that host response to differing levels of candidal
loading would vary between individuals. This led to the
second difficulty with the oral rinse technique, namely
determining what level of reduction in colony count, in
comparison with the baseline assessment, was
representative of improvement. An entirely arbitrary
level of 50% or greater reduction in colony count was set
as the criterion to indicate that a mycologic improvement
had occurred in an individual patient.
The best mycologic response was seen at one week in both
treatment groups. After this assessment the number of
patients mycologically cured or improved gradually
declined, representing re-colonisation in patients who
had been yeast free, and a return to pre-treatment yeast
densities in others. No more than half the patients were
mycologically cured at any time. At one and four weeks
the number of mycologic cures was greater in the
amphotericin group than in the fluconazole group and at
four weeks this difference was statistcally signifcant.
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The difference at four weeks is not surprising given that
the amphotericin group received a longer course of
treatment. What is perhaps surprising is that at four
weeks the mycologic response in the amphotericin group
had already begun to decline when most patients had only
very recently completed treatment.
Apart from the length of treatment, there are other
possible explanations for the slightly better mycologic
response seen in the amphotericin group. In order to be
effective an antifungal drug must reach the site of
infection and yeast proliferation. In denture stomatitis
it must reach the palatal mucosa and the fitting surface
of the upper denture. This is dependent both upon patient
compliance and the mode of drug adminstration. Compliance
with treatment is difficult to assess but in the present
study only two patients were excluded from efficacy
analyses owing to admitted poor compliance. Both patients
were in the amphotericin group. The commonest reported
side effect of treatment was nausea. Three patients
reported this problem and all were in the amphotericin
group. Subjectively it seems reasonable to expect
patients to comply more readily with taking one capsule
daily for two weeks than with sucking four lozenges daily
and spreading cream on the fitting surface of the denture
for a month. Amphotericin lozenges were allowed to
dissolve in the mouth with the dentures removed.
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Amphotericin cream was then applied directly to the
fitting surface of the denture. Assuming good compliance,
therefore, amphotericin would have had good access to
yeasts in the denture plaque and on the palatal mucosa.
Fluconazole is well distributed in saliva and serum. The
drug may therefore have had access to the palatal mucosa
and denture plaque via serum exuded through the palatal
lesions. However the extent to which this would have
occurred is unknown. If saliva was unable to flow freely
beneath the fitting surface of a retentive denture the
effectiveness of fluconazole would be reduced. Provided
the patient removed the dentures at night, fluconazole in
saliva would have some access to the palatal mucosa.
However it is conceivable that, in some cases, the drug
had no access to the denture plaque at all.
A further interesting difference between fluconazole and
amphotericin was observed, that was in regard to the
effect on yeast species. Candida albicans was isolated
from approximately 70% of sites at the baseline
assessment and was by far the commonest species
identified. Both fluconazole and amphotericin were
effective in reducing the frequency of isolation of this
species. Candida glabrata was isolated in 11 patients
at the baseline assessment (16.4% of all sites).
Amphotericin was effective in reducing the frequency of
isolation of C. glabrata but in the fluconazole group
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the frequency of isolation of this species remained the
same throughout the study, representing the persistent
isolation of the organism from the same patients. This
suggests that the strains of C. glabrata present were
resistant to fluconazole. This finding confirms two
previous reports of resistance of Candida glabrata to
fluconazole, even when administered in high
doses237'238. The numbers in the present study were too
small to prove an association between the persistence of
C. glabrata and clinical failure of treatment. However
infection with Candida glabrata should be suspected in
patients with denture stomatitis or any other form of
oral candidosis, who fail to respond to fluconazole
treatment. Ideally yeasts should be cultivated and the
species identified before treatment is commenced but this
does not rule out the possible emergence of resistant
organisms at a later stage.
Having considered the mycologic changes brought about by
antifungal treatment it is necessary to inquire how far
these changes explain the clinical response observed. In
general terms the mycologic and clinical responses were
similar. Treatment brought about an improvement which was
followed by relapse. In terms of the whole patient group,
clinical response appeared to lag behind mycologic
response. This seems reasonable; elimination of infection
is followed by healing of the lesions and re-infection is
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followed by a return of signs and symptoms. However when
individual patients were studied the relationship between
clinical and mycologic responses was far from clear.
The clinical and mycologic responses for each individual
patient at each follow-up visit were examined to see how
often the two "agreed". It was taken that failure to show
a mycologic improvement would be accompanied in the same
patient by failure to improve clinically. Similarly
mycologic improvement should be accompanied by clinical
improvement. At the four week visit such agreement was
found in only 30% of fluconazole patients and 60% of
amphotericin patients. If there was a true time lag
between clinical and mycologic response it might be more
appropriate to compare the mycologic response at one
visit with the clinical response at the next visit. When
this theory was examined correlation was only marginally
better. This poor correlation prompted examination of
other possible indicators of mycologic improvement. The
palate, fitting surface of the denture and the tongue
were the commonest sites of yeast isolation. By the one
week visit yeasts had been eliminated from approximately
half of these sites. Failure to cultivate yeasts from the
palate and/or the fitting surface of the denture might be
considered to be a reasonable indicator of mycologic
improvement. When tested against clinical response, this
mycologic indicator did indeed show better correlation.
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At the four week visit there was agreement between
mycologic and clinical response in 52% of fluconazole
patients and 73% of amphotericin patients. As an
indicator of mycologic improvement, therefore, failure to
grow yeasts from the palate or denture seems more
relevant to the clinical response than does reduction in
oral rinse derived colony counts.
Nonetheless, using either mycologic indicator,
correlation between mycologic and clinical events was
less than might be expected for a disease considered to
be primarily a yeast infection. An explanation for this
might be the inherent imprecision in both clinical and
mycologic assessments. The difficulties of assessing
clinical improvement have been discussed (see Comment on
Clinical Methods, Chapter 3). The elimination of
subjectivity and ensuring consistency of judgement over
the course of a study will present problems whatever
method is used. In at least one other study, palatal
erythema was scored and lesions photographed and
correlation between mycologic and clinical events was
still found to be poor13. There appears to be no
guarantee that increasing the apparent sophistication of
an assessment also increases its reliability. Indeed
improvement judged, for example, by a change of one point
on a five point scale, may be clinically irrelevant. The
merit of the method adopted in the present investigation
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was that "no change, marked improvement or cure" at least
has relevance to the everyday clinical situation.
The limitations of the oral rinse technique for the
quantitation of yeasts in the mouths of denture wearers
have already been discussed. In addition the use of a 50%
reduction in the resulting colony counts may have been
inappropriate as an indicator of improvement. However
there is no suggestion in the literature of what might be
considered a significant reduction. Failure to grow
yeasts from swabs of the palate and denture might be
thought less equivocal. In fact the growth of yeasts from
swabs may rely upon such factors as the area swabbed, the
pressure used and the means of transport to the
laboratory. However it does not seem unreasonable to
suggest that elimination of yeasts, as judged by
cultivation from swabs, is indicative of a drastic
reduction in their number.
It is clear that comparison of clinical and mycologic
responses is, in effect, comparison of two estimates. It
is therefore not surprising that they frequently fail to
agree. However in the present study, when clinical
response was unequivocal, correlation with mycologic
events was clear. Patients who demonstrated an excellent
clinical response, that is they were cured and remained
cured throughout the study, were either mycologically
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cured or showed a drastic,
number of sites from whic
colony counts. Patients who
throughout the study showed
yeasts at all sites. Hence
mycologic events were open
between the two was apparent
sustained reduction in the
h yeasts were isolated and in
remained clinically unchanged
continued heavy growth of
when neither clinical nor
to doubt the correlation
From these observations it appears that sustained
clinical cure of denture stomatitis is associated with
elimination or near elimination of yeasts from the mouth.
In those patients not cured but clinically improved,an
association with reduction in yeast numbers was more
difficult to demonstrate because of the imprecision
involved in assessing both clinical and mycologic status.
It is therefore necessary to look beyond individuals to
the experimental group as a whole. Here the overall
results suggest that clinical improvement is associated
with mycologic improvement and that relapse and
recurrence are associated with recrudescence of yeast
infection.
The greatest number of patients deemed to be
mycological1y cured was observed at the one week visit
but by the twelve week assessment the number of mycologic
cures was considerably reduced. This raises a question as
to the source of re-infection. One possible source is
- 196 -
yeasts from distant endogenous sites. Fluconazole
performed slightly better than amphotericin with regard
to long term mycologic cure. The systemic drug may have
eliminated yeasts at other host sites thus reducing the
chances of auto-inoculation of the mouth. It should be
stressed again that if such an effect had occurred its
results were not obvious. It seems more likely that
yeasts were never truly eliminated from the mouth in a
large majority of patients, even in those thought to be
mycologically "cured". This is certainly possible, if
antifungals have a limited effect on non-dividing
organisms then a small number of yeast organisms could
persist on oral and denture surfaces and not be detected
by swabbing. Following completion of treatment, these
organisms could be the source of re-population. In those
patients with sustained improvement it is possible that
changes in the oral environment, specifically, improved
denture hygiene, could prevent this re-population
occurring. Unfortunately, although patients were given
instruction in denture hygiene, no assessment of this
important factor was performed after the baseline visit.
It is therefore not possible to say how denture hygiene
changed during the study and this is a valid criticism of
the experimental design. However it is revealing to look
again at the very similar study of Budtz-Jorgensen et
al13, where patients were given no instruction in
denture hygiene and where the mycologic response was
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the present study. The
given to patients in the
appear to have been
in this regard must
therefore
conclusions
One further point concerning denture hygiene should be
noted. Patients who were effectively cleaning their
dentures were removing denture plaque which contains both
yeasts and bacteria. The effect of reducing the bacterial
population cannot be discounted. However denture hygiene
will have varied in its effectiveness across the
experimental group. Also, if plaque removal alone had
been responsible for producing clinical improvement, a
more constant level of improvement throughout the study
might have been anticipated. Instead, at the four week
visit, cure or improvement was almost universal; but by
the twelve week visit there had been marked relapse and
recurrence. Thus the timing of clinical improvement was
closely related to that of antifungal drug use and
relapse and recurrence was seen after drug use was
discontinued. This suggests that the antifungal effect
was of major importance in producing the clinical
responses seen. The results therefore provide further
evidence to implicate yeasts as the primary causative
agent in denture stomatitis.
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Compliance with the treatment regimen and with denture
hygiene measures may explain why some patients responded
better than others. However it has been demonstrated that
the relationship between clinical and mycologic events
was complex. It is possible that other variables may have
influenced the outcome of treatment.
The clinical response in women was consistently better
than that in men and this difference was significant at
the one week assessment. Again better compliance is a
possible explanation. The hormonal changes which occur
during menstruation and pregnancy may cause exaggerated
gingival inflammation in the presence of microbial plaque
and the oral contraceptive pill may have similar
effects239. Pregnant and lactating women were excluded
from this study, indeed many of the women were probably
post-menopausal, although hormone replacement therapy may
also affect gingival inflammation239 . However, if such
hormonal states are sometimes responsible for increased
inflammation in denture stomatitis, as seems plausible, a
worse response to antifungal therapy, compared with that
in men, might be expected. A possible explanation for the
better clinical response seen in women arose when the
effects of smoking were considered.
Patients who smoked tobacco showed a poorer clinical
response than those who did not. This is the first study
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to have demonstrated such a relationship. The difference
between smokers and non-smokers was statistically
significant at one week but by four weeks the clinical
response in smokers appeared to have caught-up and the
difference remained insignificant at the twelve week
assessment. The response in ex-smokers tended to be
intermediate between smokers and non-smokers, although
there was only a small number of ex-smokers. Thus smoking
appeared to slow down the clinical response. With regard
to the difference in clinical response between the sexes
it is revealing to note that 56% of women but only 19% of
men were non-smokers.
Previous reports make almost no mention of a link between
denture stomatitis and smoking. There is some
epidemiological data to suggest that smoking is
associated with an increased prevelance of denture
stomatitis47-54 but there is conflicting evidence
concerning the effect of smoking on oral candidal
carriage144-145. One recent study suggested that
smoking was associated with a less homogenous oral
mycoflora when compared with non-smokers and that this
may be an important factor in oral candidosis240.
The effect of smoking on periodontal disease is well
documented. Smoking would appear to be a major risk
factor for periodontal disease241. Whereas it was
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previously thought that the association between
periodontitis and smoking was due to indirect effects,
such as poorer oral hygiene in smokers, it now appears as
though tobacco smoke exerts direct effects both locally
and sy temical l.y2 4 1 . Smoking would appear to have an
adverse effect on the outcome of periodontal
treatment242'243. This does not seem to be caused by
differences in the occurrence of periodontal
pathogens in smokers and non-smokers244, but may well
be related to the effects of smoking on the host
response2 4 5,2 4 6 (
In the present study smoking appeared to give rise to
differences in the initial presentation of denture
stomatitis. The hvperplastic/granular form of the disease
was far commoner amongst smokers than amongst
non-smokers. It is not certain that this is a causal
relationship and if it were, the mechanisms behind it
seem obscure. However the difference may have influenced
antifungal drug efficacy since it may have been difficult
to eliminate yeast organisms from the deep epithelial
crypts in the hyperplast, ic/granu lar form of denture
stomatitis. In fact the results do not support this view
since the clinical response was similar in patients with
each type of denture stomatitis.
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Refractory periodontitis refers to periodontal disease
which has persistently failed to respond to conventional
therapy. In the present study of 59 patients with denture
stomatitis, antifungal treatment failed to produce any
improvement in six patients. Of these six patients, four
were smokers. In contrast eight patients were cured and
remained cured throughout the study. Of these eight only
two were smokers. Although the numbers of very poor and
excellent responders are small there is a suggestion that
"refractory" denture stomatitis may be associated with
smoking.
It seems unlikely that smoking would exert a local effect
in denture stomatitis since the area concerned is usually
covered by the denture. However a systemic effect is
possible and this will be considered in more detail when
the immune response is discussed.
The influence of prosthodontic factors on the clinical
outcome of antifungal therapy was examined. Patients who
removed their dentures at night were no more or less
likely to be cured or improved than those who wore their
dentures constantly. Of course this judgement is
dependent upon accepting the truthfulness of the
patients' replies when questioned on this matter.
Previous studies have commented on denture wearing habits
largely in relation to the prevelance and aetiology of
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denture stomatitis. Whilst some studies claim to have
shown a relationship between constant denture wearing and
denture stomatitis22•27 •34 • 42 •55 , others have failed to
do so25-35-137. However, these studies have largely
failed to consider the relationship between denture
plaque levels and constant denture wearing. Advice given
to patients to remove their dentures at night is
presumably based on the view that this will lessen the
time during which the mucosa will be subjected to insult
either through trauma or from the micro-organisms in
denture plaque. If the infective aetiology of denture
stomatitis is accepted it would seem irrelevant whether a
patient with a perfectly clean denture removes it or
wears it at night. On the other hand, in a patient with
moderate or poor denture hygiene, constant wearing of the
denture may lead to more severe inflammation of the
denture bearing mucosa. Support for this view may be
derived from one study in which severe inflammation was
found to be commoner in constant denture wearers, whilst
more moderate inflammation occurred as frequently in
those who did not wear their dentures at night as in
those who did42. With regard to treatment, therefore,
it may be that once yeast levels have fallen to a certain
level, the difference between constant and day-time only
denture wearers becomes unimportant.
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Constant denture wearers taking amphotericin did not show
a better clinical response than those taking fluconazole.
The potential for continual topical drug application
therefore appears to have conveyed no particular benefit.
Clinical response was slightly better in complete denture
wearers than in partial denture wearers, although the
difference was not significant at any visit. Oral hygiene
may be more difficult in partially dentate patients and
supra and subgingival dental plaque may harbour organisms
which serve to constantly repopulate mucosal and denture
surfaces.
Overall, denture quality factors did not appear to be
important in determining the clinical outcome of
antifungal therapy. The clinical methods used for
assessing dentures were, by nature, imprecise. No method
of clinical judgement of denture quality can be without
drawbacks. However all assessments were made by the same
clinician who was unaware of the treatment prescribed.
The judgements should therefore have been reasonably
consistent and there is no reason to assume bias. A
significant association between denture quality and
clinical outcome was demonstrated for two of the six
factors assessed, but only at the twelve week visit. At
this time patients with "fair" denture retention showed
a better clinical response than those with "good" or
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"poor" retention. Also at twelve weeks patients with
"poor" denture occlusion showed a better clinical
response than those with "fair" occlusion, who in turn
did better than those with "good" occlusion. It is
difficult to explain these findings but given the overall
results relating to denture quality, their importance
should not be over emphasised. No prosthodontic treatment
was provided for any patient during this study and at the
four week assessment most patients we re clinically cured
or improved. In addition, for each denture quality factor
assessed, patients with "good", "fair" or "poor" dentures
responded equally well. These results strongly suggest
that denture quality and, by implication, trauma from
dentures, are not primary factors in the aetiology of
denture stomatitis.
Proponents of denture trauma as a major cause of denture
stomatitis have never satisfactorily explained why
denture stomatitis is so rarely seen in the mandibular
denture bearing mucosa. Prosthodontists know that a lower
complete denture is likely to be more traumatic than an
upper complete denture since it is usually less stable
and it has a much smaller denture bearing area to resist
occlusal forces. However it is possible that dentures may
be traumatic in another sense, if they are constantly and
closely applied to the mucosa. The denture fitting
surface, covered with plaque, will be held firmly against
- 205 -
the mucosal surface. The toxins and antigenic components
within that plaque are almost bound to elicit a response
in the tissues. These toxins and antigens would be
undiluted by saliva, the flow of which, beneath a well
fitting denture, would be restricted. This would apply
especially to the upper denture where good retention can
often be achieved, in contrast to that which can be
obtained in the lower. In the absence of the mechanical
washing effect of saliva and of its antimicrobial
content, an infection could become established. This
would explain why denture stomatitis is seen almost
exclusively in the maxilla. Denture trauma in this sense
requires the presence of denture plaque.
If trauma from dentures is not a primary causative factor
in denture stomatitis, it may nonetheless be a
contributory factor and there are two potential models
for the relationship between trauma and infection.
Firstly denture trauma, however defined, may be a
predisposing factor. It is axiomatic that denture
stomatitis cannot occur in the absence of a denture so
that in a sense, the mere presence of a denture
predisposes to denture stomatitis. However trauma from a
denture is conventionally understood to mean something
more than its simple presence in the mouth. One way in
which trauma may predispose to denture stomatitis has
been described in the preceding paragraph. Another is
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that mechanical trauma may give rise to inflammatory
exudate which could enhance the adhesion of yeast
organisms to acrylic112. The second model to explain
the relationship between denture trauma and infection is
that mechanical trauma could result in enhancement of an
inflammatory response initiated by yeast infection.
Whether or not trauma from dentures is a predisposing or
exaggerating factor, it is clear that if the infective
component is removed the condition should resolve. The
results of the present study support this view. If trauma
from dentures predisposes to denture stomatitis it might
be expected that patients with potentially traumatic
dentures would be more prone to recurrence. At the twelve
week fo1low-up,patients with "fair" denture retention and
"poor" denture occlusion seemed least likely to suffer
recurrence and this, together with the insignificant
effect of any other denture quality factor, would appear
to contradict the view that mechanical trauma predisposed
patients to recurrence of denture stomatitis following
treatment.
One of the denture quality factors assessed was denture
hygiene. This study employed a method of assessing
denture hygiene similar to that used in previous
investigations46'51-231. However the use of a plaque
disclosing solution would probably have produced more
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useful results. The role of denture hygiene in the
clinical responses seen in this study has already been
I
discussed and its benefit deduced by comparison with
other reports.
At the baseline assessment the denture hygiene of
non-smokers tended to be slightly better than that of
smokers. However given the limitations of the method of
assessment used this finding should be viewed with
caution. In any case the initial denture hygiene
assessment did not appear to be related to clinical
outcome and would therefore not explain the poorer
outcome seen in smokers.
Total and specific anti-candidal antibodies were measured
in serum and saliva throughout the study. Antibody levels
were found to vary widely between patients and only very
small changes were observed between visits. The absence
of a marked effect of antifungal treatment on antibody
levels is in agreement with some previous
reports169'178 but in disagreement with
others171'173. None of these previous studies involved
measurement of both serum and salivary antibodies. The
wide range of antibody levels observed in the present
study is probably indicative of considerable individual
variation in the immune response to yeast organisms. The
failure of antifungal agents to bring about a reduction
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in antibody levels is probably related to the kinetics of
the immune response. It is likely that yeasts were
completely eliminated in only a very few patients and
even in these re-infection occurred quite rapidly. It is
perhaps not surprising, therefore, that the humoral
immune response appeared to be sustained throughout the
twelve week study period, particularly since in most
patients the infection was of a long standing nature.
It was difficult to relate the humoral immune response to
the density of yeast colonisation in the mouth. This may
be partially explained by the method used for
quantitation of yeast organisms, the possible limitations
of which have already been mentioned. In addition yeast
colonisation at other host sites would also presumably
stimulate an immune response which would effect serum
antibody levels. Colonisation of the gut would also
effect the mucosal immune system and possibly, therefore,
antibody levels in saliva. The influence of such factors
in the present study is unknown but it is small wonder
that the immune response varied so much and that it was
difficult to relate both to oral yeast levels and to
clinical outcome. Even if the level of yeast colonisation
throughout the body had been the same for each individual
it is likely that the immune response would still have
varied.
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One factor which was seen to exert a significant effect
on the humoral immune response was smoking.
Immunoglobulin levels, especially in serum, were
frequently significantly higher in non-smokers than in
smokers. In particular total serum IgG, total serum IgA,
and serum anti-candidal IgG were effected. This would
appear to be the first report of such an effect in
patients with denture stomatitis and indeed in oral
candidosis in general. This may help to explain why the
clinical outcome of antifungal therapy in smokers was
poorer than in non-smokers.
It is now well established that tobacco smoking may have
wide ranging effects on the immune system247. With
possible relevance to oral disease, smoking has been
shown to cause depression of salivary jgA248'249
although these studies did not involve patients with oral
candidosis. Smoking has also been shown to impair serum
IgG levels against specific periodontal pathogens246 .
However understanding of the effects of smoking on the
immune response remains incomplete and relating the
specific immune defects seen to clinical disease presents
considerable difficulty250.
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The effects of smoking on periodontal disease are
believed to be reversible241 and the present study
suggests that this may also be true for the effects on
denture stomatitis since ex-smokers tended to show a
clinical response intermediate to that of smokers and
non-smokers.
The cellular immune response was studied seperately in a
preliminary study employing a lymphocyte transformation
test. A consistent finding in two patients with denture
stomatitis and two patients with candidal leukoplakia was
an increased stimulation index of leukocytes challenged
with Candida antigen after antifungal treatment
compared with that seen in leucocytes obtained before
treatment. When challenged with PHA and pokeweed mitogen
however, the stimulation indices of leucocytes obtained
from these patients before and after treatment were
similar. This may suggest that chronic candidal infection
causes suppression of the cellular immune response but
that this effect is quite specific. It may be that only
the ability to respond to Candida antigen is inhibited,
although other antigens were not tested. There has been
only one other study of lymphocyte transformation in
denture stomatitis and in this only PHA mitogen was
used181. No difference was found between the response
of control and patient leucocytes and the study is, in
this respect, in agreement with the present study. In one
- 211 -
study lymphocytes from patients with unspecified chronic
candidosis had a lower stimulation index than controls
when challenged with Candida antigen but the PHA
induced lymphocyte transformation was similar in both
groups174 . These findings correlate well with those
of the present study. Studies using the leucocyte
migration test have also suggested that cellular immunity
is depressed in patients with denture stomatitis178.
Suppressor T cells have been shown to emerge in cultures
of human lymphocytes stimulated by a polysaccharide from
Candida albicans251 and this mechanism could be
involved in the depressed cellular immunity seen in
denture stomatitis.
The effects of smoking on the cellular immune response
were not examined in the present investigation. However
smoking is known to effect cellular immune
function247 , including migration and phagocytosis in
polymorphonuclear leucocytes derived from the oral
cavity2 5 2 •2 5 3 .
In an experimental model in monkeys, the cellular immune
response was found to develop concomitantly with the
clearing of a denture stomatitis-1ike infection which had
been induced by inoculation of yeasts beneath an acrylic
plate96. It is important to note that the infection
resolved spontaneously, possibly as a result of the death
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of the yeast organisms. It may be, therefore, that
cellular immunity developed as the suppressive effect of
Candida decreased. The humoral immune response
developed later and as the antibody titre rose the
cellular immune response declined. In animals treated
with azathioprine the infection persisted although the
clinical picture was changed from one of erythema to one
of thrush. In these animals the cellular immune response
was suppressed but the humoral immune response was strong
and early. This would seem to indicate that cellular
immunity is associated with clearing of the infection in
this model and that when this is suppressed humoral
immunity develops rapidly as a second line of defence.
However this model has only limited relevance to denture
stomatitis in humans which is often chronic in nature and
in which yeasts would appear to flourish in a favourable
environment. The depression of cellular immunity in
denture stomatitis would appear to be due to chronic
candidal infection and it would not be surprising if its
effects were less dramatic than those produced by drugs
such as azathioprine.
The association between humoral and cellular immune
responses in humans with denture stomatitis has been
studied and an inverse relationship between the two
demonstrated178. Cellular immunity was restored
following antifungal therapy but serum antibody levels
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remained the same. Cellular immunity was shown to be
particularly depressed in patients with the
hyperplastic/granular form of denture stomatitis.
From the results of the present investigations and those
of previous studies a possible model for the immune
response in denture stomatitis can be postulated. Chronic
candidal infection causes a degree of suppression of the
cellular immune response. The humoral immune response,
though present, is overwhelmed by yeast organisms which
are continually being' replenished. The humoral immune
response is therefore unable to clear the infection but
is able to confine it. Serum antibodies may be more
important in this role since the denture excludes, to a
varying extent, salivary antibodies. Antigen-antibody
reactions are probably responsible for the inflammation
seen. When anti-fungal treatment is instituted the
number of yeast organisms is reduced, cellular immunity
is restored and together with humoral immunity the two
may contribute to clearing of the infection. However
following cessation of antifungal treatment, if
re-infection is rapid, antibody levels will be sustained
and cellular immunity will again decline. In tobacco
smokers cellular immunity may be further suppressed and
in addition the humoral immune response is also
suppressed. These patients therefore respond more slowly
to antifungal therapy and denture stomatitis may only
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show signs of resolution once yeast numbers have been
considerably reduced by the drug.
If antigen-antibody reactions are responsible for
inflammation in denture stomatitis then initial
inflammation ought to have been less in smokers than in
non-smokers. It could be argued that this was indeed the
case. Although the hyperplastic/granular form of the
condition was far commoner amongst smokers than
non-smokers this type of denture stomatitis is not
necessarily associated with the greatest degree of
erythema. The diffuse erythematous form of the disease
was twice as common in non-smokers as smokers. Smoking
may therefore be associated with apparently less severe
inflammation but the inflammation which is seen in
smokers may nonetheless be more resistant to treatment.
It is interesting to note that in a previous report,
suppression of cellular immunity was most marked in
patients with the hyperplastic/granular form of denture
stomatitis178 and in the present study
hyperplastic/granular disease was found most commonly
amongst smokers. In the previous study the influence of
smoking was not considered. It is possible that smoking
is independent1y associated with both
hyperplastic/granular denture stomatitis and with
impaired immune responses. However it is also possible
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that the association between smoking and the
hyperplastic/granular form of the disease is mediated by
the immune response. A recent report has indicated that
dentate patients with AIDS may develop paplillary
hyperplasia of the palate associated with candidal
infection254. The patients were all severely
immunocompromised and had long standing oral candidosis.
It seems possible therefore that mucosal proliferation may
occur in patients with impaired immunity in response to
chronic yeast infection, possibly as a defence mechanism.
Much of the work which has been done on denture
stomatitis has concentrated on the external causes of the
disease, such as yeast infection and denture trauma.
Yeasts, present largely in denture plaque, would seem to
be the most important of these external causes. However
it is clear that the balance between host and parasite is
of fundamental importance in this disease. Any factor
which affects the host defence mechanisms may influence
the onset of the disease and its response to treatment.
Unfortunately the host response is frequently beyond the
clinicians control but controlling the parasite is more
feasible. Treatment of denture stomatitis must aim to
reduce levels of denture plaque. Antifungal drugs may be
a useful adjunct but, in the absence of good denture




The results of the investigations described in this
thesis suggest the following conclusions:
1. To obtain long term clinical success in the treatment
of denture stomatitis, antifungal agents must achieve
elimination or near elimination of yeast organisms from
the mouth and this mycologic status must be sustained.
2. Antifungal agents rarely achieve complete elimination
of yeasts from denture and mucosal surfaces.
3. Where any yeasts remain after antifungal therapy,
effective denture hygiene measures are probably crucial
in preventing repopulation of denture and mucosal
surfaces.
4. The necessary degree of reduction in yeast numbers can
probably be more reliably demonstrated by absence of
growth from swabs of the palatal mucosa and denture
fitting surface than from reduction in colony counts
derived from oral rinse samples, whether or not the
denture is worn during rinsing.
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5. Fluconazole and amphotericin are equally efficacious
in the treatment, of denture stomatitis. Neither drug is
associated with any serious or frequent side effect.
6. The response of denture stomatitis to antifungal
treatment is poorer in smokers than in non-smokers.
7. The humoral immune response is depressed in smokers
compared with non-smokers. This may explain the poorer
clinical response of smokers to antifungal therapy.
8. The hyperplastic/granular form of denture stomatitis
is commoner in smokers than in non-smokers. This may be
related to the depressed immunity seen in smokers.
9. The quality of the dentures themselves does not appear
to influence the outcome of antifungal treatment of
denture stomatitis. By implication, therefore, denture
trauma is probably of only secondary importance in the
aetiology of the condition.
10. Chronic candidal infection may cause suppression of
the cellular immune response but this appears to be
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Enzyme-Linked Immunosorbent Assay: Reagents.
The preparation of the reagents was essentially the same
as that described by Wray235. The coating buffer for
sensitising the the plates, a carbonate-bicarbonate
buffer (pH 9.6), consisted of 1.59 gms of Na2CO3,
2.93 gms of NaHC03 and 0.2 gms of NaN3 made up to one
litre with distilled water. This was stored at 4 0 C for
not more than two weeks. The phosphate buffered
saline-tween 20 mixture (PBS-tween) consisted of 8 gms of
NaCl, 0.2 gms of KH2 PO4 , 2.9 gms Na2HP04 .12H2O,
0.2 gms of KC1 and 0.5 mis of tween-20 (Sigma, Poole,
Dorset, UK) in one litre of distilled water. The pH of
the solution was 7.4. For alkaline phosphatase
conjugates, p-nitrophenyl phosphate tablets (Sigma 104
phosphate substrate tablets, 5mg, Sigma, Poole, Dorset,
UK) were used for convenience. Immediately before use,
one 5 mg tablet was dissolved in each 5 mis of
diethanolamine buffer already warmed to room temperature.
The diethanolamine buffer contained 97 mis of
diethanolamine (Sigma, Poole, Dorset, UK) , 800 mis of
distilled water, 0.2 gms of NaN3 and 100 mg of
MgCl2 .6H20; 1 M HC1 was added until the pH reached




Complete crosstabulations of symptom severity at each














































































































































































































































































































































































































































































































































































































































Analytical Profile Index System.
Selected colonies were sampled using a sterile wooden
applicator which was then used to inoculate molten
Sabouraud's medium. This suspension was then inoculated
into each of the plastic cupules on the API strip. One
cupule contained this suspension only, and served as a
control, the remainder contained dehydrated carbohydrate
substrates. The strips were incubated at 30 °C for 72
hours. The ability of the yeast sample to assimilate each
substrate was indicated by an increase in turbidity
greater than that demonstrated by the control. The
assimilation reactions of each test sample were used to
produce a profile number, according to the manufacturer's
instructions, which was then compared with the profile
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Comparative trial of fluconazole and amphotericin in the
treatment of denture stomatitis
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The efficacy of fluconazole and amphotericin in the management of denture stomatitis was investigated in a
comparative trial. Patients were assessed clinically, hematological^ and mycologically at the time of entry into the study and at
1, 4. and 12 weeks thereafter. A total of 29 patients were selected at random to receive 50 mg of fluconazole daily for 14
days; 30 patients were selected to receive amphotericin lozenges and cream for 28 days. Clinical response rates were similar in
both treatment groups throughout the study. The best mycologic response was noted after 1 week whereas the best clinical
response was observed after 4 weeks. Clinical evidence of relapse and recurrence at 12 weeks was a common finding
irrespective of treatment. Side effects were uncommon in both groups. (Oral Surg Oral Med Oral Pathol 1993;76:35-9)
Denture stomatitis is a condition characterized by
erythema of the denture-bearing mucosa, which oc¬
curs almost exclusively in the maxilla. Newton1
described three types on the basis of clinical appear¬
ance, and this classification was later modified by
Budtz-Jorgensen and Bertram2 who chose the terms
simple localized, simple diffuse, and granular to
describe the inflammatory changes seen. The preva¬
lence of the condition among denture wearers has
been variously reported as between 25% and 65% de¬
pending on the population studied.3"6 The condition
may therefore be considered common.
The cause of denture stomatitis is often said to be
multifactorial, but denture trauma, denture plaque,
and candidal infection seem to be among the most
important causes.7 Consequently treatment includes
correcting denture faults, improving denture hygiene,
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and, although some would question its necessity, an¬
tifungal therapy.
Up to this time, the antifungal agents used have
been the polyenes—nystatin and amphotericin, and
the imidazole—miconazole, all topically applied.8
Reports suggest that these drugs are effective in pro¬
ducing an initial improvement in the condition but
that recurrence rates are high and treatment regimens
tend to be prolonged.9"14 Systemically administered
imidazoles, such as ketoconazole, have not been used
routinely because of the superficial nature of the le¬
sion and the possibility of hepatotoxic reactions.
Fluconazole is a recently introduced, bis-triazole,
systemic antifungal agent, which is very well absorbed
orally. It is widely distributed throughout body fluids
including saliva and has an elimination half-life of
approximately 30 hours.15 Fluconazole has been
shown to be effective in the management of superfi¬
cial fungal infections such as vaginal candidiasis16
and oropharyngeal candidiasis in patients who are
HIV-positive.17,18 A feature of these reports has been
the rapidity of clinical improvement observed. Lamey
et al.19 described the successful use of fluconazole to
treat a single patient with chronic hyperplastic can¬
didiasis. Fluconazole has been shown to be efficacious
in the treatment of denture stomatitis in one open,
noncomparative study20 and in one placebo-con-
35
36 Bissell, Felix, and Wray
trolled trial.21 Thus far there has been no comparative
trial of fluconazole and a standard therapeutic regi¬
men in the treatment of denture stomatitis.
The aims of this study were to determine the effi¬
cacy of systemic fluconazole versus topical ampho¬
tericin in the treatment of denture stomatitis and the
relative recurrence rates after each treatment.
METHODS
Diagnosis
Patients were entered into the trial on the basis of
a clinical diagnosis of denture stomatitis and myco-
logic investigation for the presence of yeast organ¬
isms. The clinical appearance was classified as local¬
ized erythematous, diffuse erythematous, or hyper¬
plastic granular. (Localized erythematous was defined
as a patchy form of erythema rather than the
pin-point hyperemia described by Newton as type I
denture stomatitis.)
Patients
Fifty-nine patients with denture stomatitis were
recruited after explanation and consent from those
who attended the Prosthetics Department of Edin¬
burgh Dental Hospital. Of these 16 were men with a
mean age of 51 years (range, 22 to 77 years) and 43
were women with a mean age of 55 years (range, 26
to 81 years). Patients were excluded from the study
for the following reasons:
1. If they were pregnant, lactating, or of child-bear¬
ing age and not using reliable contraception
2. If they had impaired renal or hepatic function
3. If they had used any other antifungal agent dur¬
ing the past 10 days
4. If they were taking barbiturates, coumarin antico¬
agulants, or oral hypoglycemic agents
5. If they had a known sensitivity to polyenes or the
azole group of antimycotics
6. If they intended to donate blood during or 3 weeks
after the study period
7. If they had a history of alcoholism, drug abuse,
psychiatric disorder, or any other problem that
might invalidate informed consent
Trial design
At the initial visit patients were assessed clinically
and mycologically, and blood was obtained for hema¬
tologic investigations (vide infra). They were then
randomly assigned to receive either 50 mg of flucon¬
azole daily for 14 days or 40 mg lozenges of ampho¬
tericin four times a day plus amphotericin cream to
place on the fitting surface of the upper denture for 28
days. Ail patients received instruction in denture hy¬
giene.
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Patients were reviewed at 1 week, 4 weeks, and 12
weeks after treatment commenced. The same clini¬
cian examined all patients at all visits and was
unaware of the medication prescribed.
Clinical assessment
Denture stomatitis was classified as aforemen¬
tioned. Clinical symptoms of burning, xerostomia,
pain, and abnormal taste were recorded as absent,
mild, moderate, or severe at each visit.
At review visits the palatal tissues were examined,
and denture stomatitis, if present, was classified. A
subjective assessment was made of the extent of any
reduction in erythema. A note was made when it was
thought a distinct clinical improvement had taken
place. Adverse events were noted.
Mycologic assessment
At each visit swabs were taken from the palate, fit¬
ting surface of the denture, tongue, floor of mouth,
and the right and left angles of the mouth. A
phosphate-buffered saline rinse sample was obtained
for quantitative analysis of yeast organisms.22 These
samples were transported immediately to the labora¬
tory where they were cultured with the use of standard
techniques.
Hematologic and biochemical investigations
A full blood cell count and estimates of serum fer¬
ritin, serum folate, and serum B [2 were obtained.
Liver function tests were also performed. The blood
count and liver function tests were repeated at
follow-up visits.
RESULTS
Of the 59 patients who entered the study, 29 were
randomly selected to receive fluconazole and 30 to re¬
ceive amphotericin. Fifteen patients in the flucona¬
zole group were smokers as were 10 in the amphoteri¬
cin group. The demography of each treatment group
and the numbers with each type of denture stomatitis
at the initial assessment are summarized in Tables I
and II.
All patients except one had yeast organisms recov¬
ered from their mouths, with Candida albicans by far
the most common yeast species isolated. The patient
from whom no yeast organisms were isolated re¬
sponded to treatment and was therefore included in
the clinical efficacy analysis although not in the my¬
cologic analysis.
Nine patients failed to complete the study accord¬
ing to the protocol, but only three patients were
excluded from all efficacy analyses: two amphotericin
patients for poor compliance and one fluconazole pa¬
tient who failed to return after the baseline visit.
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Clinical findings
The number of patients cured or improved in each
treatment group is given in Table III. The differences
between treatments were not significant at any visit.
The best cure rate was seen at 4 weeks with approx¬
imately 44% of patients in the fluconazole group cured
and 63% in the amphotericin group clinically cured.
If those cured and those who showed a marked clin¬
ical improvement are considered together, greater ef¬
ficacy is observed: after 1 week approximately 50% of
patients were clinically cured or improved in both
treatment groups. At 4 weeks this had risen to 84% for
the fluconazole group and 90% for the amphotericin
group. However, by 12 weeks, there'had been consid¬
erable recurrence, and only about 50% of patients in
each group remained cured or improved.
Very few patients experienced clinical symptoms,
and these showed no change or were improved during
the study. In this respect there was no significant dif¬
ference between treatments at any visit.
Laboratory findings
Table IV details the mycologic response to treat¬
ment. Mycologic cure was taken to be complete erad¬
ication of all yeast organisms. An arbitrary level of
50% or greater reduction in colony-forming units per
milliliter as derived from the PBS rinse was consid¬
ered a mycologic improvement. The best mycologic
response occurred at 1 week when 50% of the patients
in the fluconazole group and 68% in the amphotericin
group were cured or improved according to the crite¬
ria set. However, by 4 and 12 weeks, there had been
progressive recolonization in both groups. For indi¬
vidual patients in both treatment groups, the correla¬
tion between mycologic events and clinical status was
poor.
Hematologic investigations
At the outset five patients (four assigned to flucon¬
azole and one to amphotericin) had a low serum fer¬
ritin and two patients (both receiving amphotericin)
had a low serum folate. These deficiencies were not
corrected, and despite this, only one patient, who had
shown poor compliance, failed to respond to treat¬
ment. During treatment there were no adverse changes
in hematologic indexes or liver function tests.
Side effects
The overall incidence of adverse effects during
treatment was low. Only one patient, who was taking
amphotericin, discontinued treatment as a result of
nausea.
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Table I. Demographic details for each treatment
group
Fluconazole Amphotericin
Total number 29 30
Men 8 8
Women 21 22
Mean age (years) 50 60
Age range (years) 22-77 24-81
Table II. Classification of denture stomatitis in each
treatment group at initial visit
Fluconazole Amphotericin
Localized erythematous 1 7
Diffuse erythematous 15 17
Hyperplastic granular 7 6
Total 29 30
DISCUSSION
The results of this study indicate that systemic flu¬
conazole is as effective as topical amphotericin in the
treatment of denture stomatitis and confirm that flu¬
conazole is a safe, well-tolerated drug. The figures of
84% of patients cured or improved by fluconazole
correspond well with the 16% cured and 73% im¬
proved reported by Budtz-Jorgensen et al.21 The
higher proportion of patients cured in the present
study (44%) may be explained by the fact that the
patients were advised on denture hygiene and told to
leave their dentures out at night, whereas in the
aforementioned study the patients were given no such
instructions.
In the present study the clinical relapse and recur¬
rence rates were similar in both treatment groups with
only about half of the patients remaining cured or
improved at the 12-week follow-up visit. This is con¬
sistent with other reports that demonstrate high rates
of relapse and recurrence of denture stomatitis after
antifungal therapy,10, l4,23-25 and there are a number
of possible explanations for this.
The relationship between denture plaque, yeasts,
and denture stomatitis seems to be estab¬
lished. I4,23'26,27 The denture must therefore consti¬
tute a potential source of reinfection, and this view has
been expressed by other authors.I0,24 It follows that
successful long-term treatment ofdenture stomatitis
depends upon either the complete removal of denture
plaque, which is preferable, or the eradication of
yeasts within the plaque. Both objectives require pa¬
tient compliance, in the first case with oral hygiene
measures and in the second case with the treatment
regimen. In addition the therapeutic agent must reach
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Table III. Clinical response
/ Week 4 Weeks 12 Weeks
F A F A F A
Cured 5 9 11 14 6 5
Improved* 8 6 10 6 9 7
No change* 13 1 1 4 2 11 12
Total 26 26 25 22 26 24
F, fluconazole
A, amphotericin
•Improved and no change are in comparison with the baseline assessment.
Table IV. Mycologic response
/ Week 4 Weeks 12 Weeks
F A F A F A
Cured 8 12 3 10 4 I
Improved* 5 5 2 2 0 8
No change* 13 8 20 9 22 14
Total 26 25 25 21 26 23
F, fluconazole
A, amphotericin
•Improved and no change arc in comparison with the baseline assessment.
the site of infection and yeast proliferation, namely
the palatal mucosa and the fitting surface of the den¬
ture.
Only two patients showed poor compliance with
treatment, and both were in the amphotericin group.
Subjectively it seems reasonable to expect patients to
comply more readily with taking one capsule daily
than with sucking four lozenges and spreading cream
on the fitting surface of the denture.
The therapeutic effect of fluconazole on superficial
oral mucosal lesions is probably dependent on its
presence in saliva. If saliva is unable to flow freely be¬
low the fitting surface of a tightly fitting denture, this
might restrict the effectiveness of fluconazole. For this
reason, removing the dentures at night must be con¬
sidered an important adjunct to fluconazole treat¬
ment. The patients treated with amphotericin, as well
as sucking lozenges also placed amphotericin cream
on the fitting surface of the denture. Amphotericin
may therefore have had better access to the denture
plaque than fluconazole. In either treatment group,
failure to remove yeasts completely from the denture-
fitting surface or the lesion would predispose the pa¬
tient to recurrence of the condition after cessation of
treatment.
Reinfection from exogenous sources21 and from the
gut25 has also been suggested as a cause of relapse.
Systematically administered fluconazole might be
expected to more completely clear Candida from
other host sites.
It is difficult to draw conclusions about the cause of
relapse and recurrence after antifungal therapy ex¬
cept to say that it is probably a result of a combina¬
tion of the factors discussed.
Many studies of antifungal therapy in the
treatment of denture stomatitis have involved
an assessment of the effect on mycologic param¬
eters.10'13' 21 •23"25'27,28 In the present study the best
mycologic cure rates were seen 1 week into treatment,
but at subsequent follow-up visits there was progres¬
sive recolonization. These findings are in agreement
with previous reports.23, 25'28 Previous attempts to
assess mycologic improvement in patients not ren¬
dered yeast-free have been based on determining the
reduction in the density of growth.11"13'21'23'25,27,28
However, many of the methods used have been only
semiquantitative.13'21'25 Methods of quantitative as¬
sessment have been compared, and the imprint cul¬
ture and concentrated rinse culture methods were
found to be equally sensitive.22
In this study with the use of a concentrated oral
rinse culture and the criteria described, mycologic
improvement was not suprisingly more prolonged in
the amphotericin group that received a longer course
of treatment. In light of this it might be suggested that
fluconazole treatment should be continued longer.
However, it could also be argued that there is little
value in viewing the mycologic results in isolation, es¬
pecially because the present study and others21,28
have found poor correlation between mycologic events
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and the observed clinical status. This has been attrib¬
uted to the involvement of factors other than Candida
in the cause of denture stomatitis,28,29 but it might
equally be due to differing host responses.
Given the high rates of relapse and recurrence to¬
gether with the progressive recolonization by yeasts,
should antifungals be used to treat denture stomati¬
tis? The condition is often diagnosed when patients
request new dentures, and because inflamed tissues
offer poor support for prostheses, treatment is justi¬
fied. However, treatment should be directed primarily
toward reducing levels of denture plaque. In patients
who do not respond to this approach or in patients who
are at risk of disseminated infection, antifungal
treatment may be required. In these circumstances
fluconazole is a convenient and safe therapeutic agent.
The efficacy of fluconazole and the improved patient
compliance associated with its use also has implica¬
tions with respect to the treatment of other oral can¬
didiasis.
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Humoral immune responses in Candida-associated denture
stomatitis. D H FELIX1, V BISSELL2, D WRAY1.
(1 Department of Oral Medicine, Glasgow Dental Hospital
and School, 2 Department of Restorative Dentistry,
Edinburgh Dental Hospital, U.K. )
Previous studies have demonstrated an increased incidence
of Candida carriage and infection among cigarette
smokers when compared to non-smokers. However the
mechanisms underlying this difference remain unclear. The
aim of the present study was to investigate the effects
of cigarette smoking on the immune response in patients
with Candida-associated denture stomatitis. Fifty two
patients (24 smokers, 28 non-smokers) were investigated.
Samples of serum and whole saliva were obtained before
the start of treatment and at one, four and twelve weeks
thereafter. Total serum and salivary IgG and IgA
concentrations were measured by a commercially available
radial immunodiffusion assay (Behringwerke AG, Marburg,
Germany); serum and salivary anti-Candida IgG and IgA
levels were measured using a double sandwich ELISA
technique. Data was analysed using Mann-Whitney and
Wilcoxon rank sum non-parametric tests. Before the start
of treatment serum anti-Candida IgG levels in
non-smokers (476 _±. 98[S.E.]) were significantly higher
than in smokers ( 1 70 JL 30 ) ; p=0.001. A similar difference
was observed at all other times throughout the study.
Total serum IgG levels were higher among non-smokers at
baseline and week one (p<0.05). Total serum IgA
concentrations were higher among non-smokers at weeks
one, four and 12 (p<0.05). No significant. differences
were observed in salivary immunoglobulin concentrations.
This study provides evidence of the effects of cigarette
smoking on the immune response and may help to explain
the higher incidence of Candida carriage and infection
seen in smokers.
